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ENGLISH SUMMARY 
The central nervous system (CNS) is protected from the circulation by two 
distinct barriers: the blood-brain barrier (BBB) and the blood-cerebrospinal 
fluid barrier. These barriers protect the brain by limiting the entry of toxins, 
pathogens, and many molecules circulating in the blood. The BBB is located 
at the brains microvasculature and consists of specialised brain capillary 
endothelial cells (BCECs), which are tightly connected through so-called 
tight junction proteins. The specialised endothelial cells are supported by 
pericytes embedded in the vascular basement membrane and astrocyte 
endfeet. Interaction between the components of BBB is of outermost 
importance for proper function of the BBB. 
The protection of the brain by the BBB from unwanted substances 
circulating in the blood is under normal physiological circumstances of great 
value for maintaining a healthy brain environment. However, in the case of 
brain diseases the barrier becomes an obstacle for the delivery of drugs to the 
CNS, and much research has gone into finding a way to pass this barrier. 
Furthermore, it is now well recognised that in condition with chronic 
neurodegeneration and inflammation such as Alzheimer’s disease, 
Parkinson’s disease, and multiple sclerosis, changes of the BBB are often 
observed. These changes include increased BBB permeability, 
neoangiogenesis, changed expression of tight junction proteins, and 
basement membrane thickening. This PhD-thesis is based on four papers in 
where the BBB is investigated under normal physiological conditions (Study 
I and II) and during chronic neurodegeneration with inflammation (Study III 
and IV). 
Models of the BBB are useful tools for investigation of the responses of the 
BBB to various insults. In study I, a murine BBB model was established and 
investigated for the expression of basement membrane proteins. Murine 
BCECs (mBCECs), pericytes, and mixed glial cells were isolated and grown 
in four different experimental setups consisting of: mBCECs grown in 
mono-culture, and in co-culture with pericytes or mixed glial cells, or in 
triple-culture with both pericytes and mixed glial cells. The mBCECs grown 
in co- and triple-cultures have significant higher transendothelial electrical 
resistance (TEER) compared to the mono-culture. The contribution of the 
mBCECs to the synthesis of basement membrane proteins was investigated 
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with RT-qPCR, mass spectrometry, and immunofluorescence. The mBCECs 
expressed many major basement membrane proteins, and the gene 
expressions of laminin α5 and collagen IV were affected by the culture 
conditions. In study II, the co-culture with mBCECs and mixed glial cells 
was investigated for the expression of the neonatal Fc receptor (FcRn), 
which is believed to be involved in the transport of IgG from brain to blood. 
It was concluded that FcRn is indeed expressed albeit at low levels by the 
mBCECs. 
A rat model of neurodegeneration with inflammation was created by 
injection of the glutamate agonist ibotenic acid into the striatum. 
Subsequently, this led to death among GABAergic neurons projecting to 
substantia nigra pars reticulata (SNpr), thereby creating an imbalance 
between the glutamate projections from nucleus subthalamicus and the 
GABAergic projections from striatum to SNpr. This resulted in 
overstimulation of the neurons in SNpr, which eventually caused 
excitotoxic-induced death among the neurons in SNpr. In study III, the 
inflammatory process in response to excitotoxic neuronal death in SNpr was 
investigated, together with the handling of the increasing amount of iron, 
which accompanies the infiltration of inflammatory cells. The study revealed 
that the neurodegeneration with inflammation was prominent and ongoing 
even at post-surgery day 91. Therefore, the main purpose of study IV was to 
investigate changes of the BBB permeability, expression of basement 
membrane proteins and adhesion molecules in response to the induced 
chronic neurodegeneration with inflammation. To further investigate the 
response of the BBB to inflammation, a rat triple-culture model of the BBB 
was established and exposed to lipopolysaccharide (LPS). Increased BBB 
permeability was observed by the presence of a prominent albumin 
immunoreaction in the SNpr. In addition, an increased gene expression of 
both intercellular adhesion molecule 1 (Icam1) and tissue inhibitor of 
metalloproteinases 1 (Timp1) were observed in the in vivo model of chronic 
neurodegenerative with inflammation and in the in vitro BBB model in 
response to LPS exposure. In vitro, the increased expression of Icam1 was 
observed among BCECs and astrocytes, whereas the increased expression of 
Timp1 was observed in pericytes and astrocytes. This indicates that these cell 
types contribute to the increased gene expression of Icam1 and Timp1 in vivo 
in response to excitotoxic-mediated neuronal death in SNpr.  
VI 
DANSK RESUME 
To forskellige barrierer adskiller centralnervesystemet (CNS) fra det 
cirkulerende blod: Blod-hjernebarrieren (eng. blood-brain barrier (BBB)) og 
blod-cerebrospinalvæskebarrieren. Disse to barrierer beskytter hjernen ved at 
forhindre, at skadelige stoffer fra blodbanen kan komme ind i hjernevævet. 
BBB er lokaliseret i hjernens kapillærer og består af specialiserede 
hjernekapillærendotelceller (eng. Brain capillary endothelial cells (BCECs)), 
som er tæt forbundet af såkaldt ”tight junction”-proteiner. BCECs 
understøttes af pericytten, som er indlejret i den vaskulære basalmembran og 
astrocyt endefødder. Samspillet mellem BCEC, pericyt og astrocyt er vigtig 
for, at denne barriere kan opretholdes.  
BBB beskytter som sagt hjernen imod skadelige stoffer cirkulerende i 
blodbanen. Dette er under normale fysiologiske omstændigheder en fordel, 
men ved forskellige neurologiske sygdomme i CNS bliver denne barriere en 
forhindring for leveringen af lægemidler, hvorfor en del forskning har 
adresseret dette problem og prøvet at finde måder, hvorpå denne barriere kan 
passeres. Ydermere er det nu vist i flere studier, at BBB ændres ved 
neurodegenerative sygdomme med inflammation som f.eks. Alzheimers 
sygdom, Parkinsons sygdom og multiple sklerose. Disse ændringer 
inkluderer blandt andet øget BBB permeabilitet, neoagiogenese, ændret 
ekspression af ”tight junction”-proteiner og fortykket basalmembran. Disse 
ændringer formodes at kunne øge lægemiddelleveringen til CNS. Ph.d. 
afhandlingen er baseret på fire studier, hvor forskellige aspekter af BBBen 
undersøges under normale fysiologiske omstændigheder (studie I og II) samt 
ved kronisk neurodegeneration med inflammation (studie III og IV).  
In vitro BBB modeller er brugbare i forhold til at studere interaktion 
mellem de forskellige celler, som udgør BBB eller responset på forskellige 
stimuli. Begge undersøgelser ville være hen imod umulige at studere in vivo.  
Formålet med første studie var derfor at etablere en in vitro model for den 
murine BBB. murine BCECs (mBCECs), pericytter og en kultur af blandede 
gliaceller blev isoleret fra hjerner fra mus og groet i fire forskellige setups 
bestående af: mBCECs groet i monokultur, i co-kultur med pericytter eller 
blandede gliaceller eller i triple-kultur med både pericytter og blandede 
gliaceller. Både co- og triple-kulturerne havde signifikant højere 
transendothel elektrisk resistent (TEER) i forhold til mono-kulturen. 
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Derudover blev mBCECs bidrag til basalmembranen undersøgt med RT-
qPCR, massespektrometri og immunofluorescens. mBCECs producerede 
forskellige basalmembran protein in vitro og gen-ekspressionen af både 
laminin α5 og collagen IV α1 var påvirket af dyrkningsforholdene. I studie II 
blev co-kulturen med mBCECs og blandede gliaceller undersøgt for 
udtrykket af neonatal Fc receptoren (FcRn), da denne receptor menes at være 
involveret i transport af IgG fra hjerne til blod. Det blev konkluderet at 
mBCECs har et lavt udtryk af FcRn.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
En rottemodel for kronisk neurodegeneration med inflammation blev 
induceret ved at injicere glutamat agonisten ibotensyre i striatum. Dette 
medfører, at mange af de GABAnerge neuroner, der projicerer til substantia 
nigra pars reticulata (SNpr), dør, og derved skabes der en ubalance mellem 
glutamat projektionerne fra nucleus subthalamicus til SNpr og de GABAerge 
projektioner fra striatum. Resultatet af denne ubalance er, at neuronerne i 
SNpr bliver overstimuleret, hvilket fører til excitotoksisk medieret 
neurodegeneration i SNpr. I studie III blev den inflammatoriske proces i 
forbindelse med excitotoksisk medieret neurodegeneration samt 
håndteringen af den øgede mængde af jern, som akkompagnerer den øgede 
infiltration af inflammatoriske celler, undersøgt. Studiet viste blandt andet, at 
både den neurodegenerative proces og den medførende inflammation var 
stærk og vedvarende i SNpr selv 91 dage, efter ibotensyre var blevet injiceret 
i striatum. I studie IV blev betydningen af kronisk neurodegeneration med 
inflammation derfor undersøgt i forhold til BBB permeabilitet og ændringer 
i genekspression af forskellige basalmembran og adhæsionsmolekyler. 
Ydermere, for at undersøge den cellulære respons af BBB på inflammation, 
blev en rotte BBB model bestående af BCECs, pericytter og astrocytter 
etableret og eksponeret for lipopolysaccarid (LPS).  
Studiet viste tilstedeværelse af albumin immunoreaktion i SNpr, hvilket 
indikerer, at BBB havde været komprimeret i løbet af de 91 dage efter 
injektion af ibotensyre i striatum. Derudover var genekspressionen af Icam1 
og Timp1 opreguleret i både modellen for neurodegeneration med 
inflammation og i BBB-modellen. I BBB-modellen blev den øgede 
ekspression af Icam1 observeret i BCECs og astrocytterne, og den øgede 
ekspression af Timp1 blev observeret i pericytten og astrocytten, hvilket 
indikerer, at disse celletyper bidrager til den øgede ekspression af Icam1 og 
Timp1 observeret in vivo som respons på excitotoksisk medieret 
neurodegeneration i SNpr. 
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Chapter 1. The blood-brain barrier (BBB) 
The central nervous system (CNS) is protected from the circulation by two 
distinct barriers, i.e. the blood-brain barrier (BBB) and the blood-
cerebrospinal fluid (CSF) barrier that both limit the penetration of toxins, 
pathogens, and many molecules into the brain (Abbott et al., 2006, Daneman 
et al., 2010a).  The BBB is located at the brain microvasculature and denotes 
the major site of blood-CNS interchange (Mattsson et al., 2014). The BBB 
consists of thin non-fenestrated brain capillary endothelial cells (BCECs) 
connected by intermingling tight junctions (TJ) and adherence junctions 
(AJ). The BCECs are surrounded by pericytes embedded in the vascular 
basement membrane. The outer part of this basement membrane is further 
invested by astrocytic endfeet, and to some extent also projections from 
microglia, oligodendrocytes, and neurons. All together, these cells are 
referred to as the neurovascular unit (NVU) (Fig. 1) (Abbott et al., 2010). 
Since the BBB restricts the entry of many molecules into the brain, the 
barrier also becomes an obstacle for the treatment of neurological disorders, 
as it also restricts the entry of many drugs. However, much research carried 
out in recent years acknowledges that the vascular integrity of the brain gets 
compromised in common neurological disorders like Alzheimer’s disease 
(Biron et al., 2011, Zlokovic, 2011, Dorr et al., 2012), Parkinson’s disease 
(Carvey et al., 2005, Patel et al., 2011), stroke (Fukuda et al., 2004), epilepsy 
(Marchi and Lerner-Natoli, 2012) and multiple sclerosis (Ortiz et al., 2014).   
Hypothetically, the pathological changes of the BBB in such neurological 
disorders may indirectly increase the success of drug delivery across the 
BBB. 
The following paragraphs introduce the cellular compositions of the BBB 
and the associated basement membrane. Furthermore, the creation of in vitro 
BBB models is covered, including an introduction to some of the changes 
that can be observed at the BBB in neurological disorders with 
inflammation.  
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Figure 1. Schematic illustration of the neurovascular unit (NVU). The endothelial 
cell (E) lines the surface of the blood-vessel and is supported by the pericyte (P), 
which is embedded in the basement membrane (BM).The endothelial cells are 
further supported by astrocytic (A) endfeet and in close proximity are both the 
microglial (M) cells and neurons (N) located. 
1.1. The composition of the BBB 
1.1.1. Brain capillary endothelial cells (BCECs) 
In brain capillaries, the BBB is primarily formed by BCECs, pericytes, and 
astrocytic endfeet. In larger vessels like arteries, arterioles and veins, the 
pericyte are replaced by smooth muscle cells. The BCECs are special 
compared to capillary endothelial cells in other parts of the body due to their 
tight interconnections made by TJs and AJs, their lack of fenestrations, and 
low vesicular transport. The AJs consist of different cadherins, which span 
the intercellular cleft. They are attached to the cytoplasm of the cells through 
catenins. The AJs are primarily responsible for holding the BCECs together, 
thereby giving structural support to the BCECs. The TJs are the primary 
component of the BBB that prominently restrict the paracellular transport 
across the BBB. The TJs consist of claudins and occludin, which span the 
Chapter 1. The blood-brain barrier (BBB) 
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intercellular cleft and are linked to the cytoplasmic scaffolding proteins 
zonulae occludentes (ZO1-3) and cingulins. Furthermore, the junctional 
adhesion molecules (JAMs) also span the intercellular cleft and take part in 
the restriction of the paracelluar transport (Wolburg et al., 2009, Abbott et 
al., 2010). The restriction in the free movement of ions across the BBB 
results in high in vivo transendothelial electrical resistance (TEER). The 
TEER in rat pial vessels was measured to ~1500 Ω*cm2 (Butt et al., 1990). 
In frog microvessels an average of 1870 Ω*cm2 has been measured (Crone 
and Olesen, 1982). However, these measured values come nowhere near the 
calculated electrical resistance by Smith and Rapoport reporting a 
cerebrovascular permeability value of 8000 Ω*cm2 in the brain of rats (Smith 
and Rapoport, 1986).
 
 
The BCECs are the primary cell type responsible for ensuring the supply 
of essential nutrients into the brain (Fig. 2). O2, CO2, and small lipophilic 
agents can relatively freely cross the lipid membrane. However, the BCECs 
abundantly express ABC efflux transporters, which transport many crossing 
small lipophilic agents back to the blood. The ABC efflux transporters also 
restrict the entry of many toxins circulating in the blood. Few polar 
molecules, e.g. alcohols and morphine, can pass the BBB by paracellular 
diffusion through the TJs. Amino acids and glucose are transported across 
the BCECs via carrier mediated transport. This transport can be bi-
directional, determined by the concentration gradient, or uni-directional, 
involving the exchange of one substance for another. Larger molecules like 
proteins are primarily transported through receptor mediated transcytosis 
(RMT) or adsorptive mediated transcytosis (AMT). Immune cells can also 
cross the BBB through a process called diapedesis. The immune cells enter 
the luminal side of the BCECs and before creating an opening at the 
abluminal side, the entry side is closed, thereby leaving the BBB intact. The 
immune cells can also cross the BBB paracellularly by modulation of the TJ 
proteins (Abbott et al., 2006, Abbott et al., 2010).  
The special features of the BCECs are important for protecting and 
maintaining brain homeostasis although it also creates a major obstacle in 
the delivery of drugs to CNS. Therefore, several attempts are made in order 
to overcome the BBB. One approach is to target a transporter at the BBB, 
thereby using the BBBs own shuttle system to transport drugs across the 
BBB. One such target is the transferrin receptor (TfR). TfRs are expressed in 
many tissues, however, it is uniquely expressed at the luminal surface of the 
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capillaries of the brain (Jefferies et al., 1984), making the TfR a putatively 
perfect target for the delivery of drugs to the CNS. Bispecific antibodies 
targeting both the BCEC TfRs and a target in the diseased brain parenchyma 
are promising candidates for the treatment of brain disorders (Yu et al., 
2011, Yu et al., 2014). However, the fate of the antibodies in the brain 
parenchyma is not well understood. The neonatal Fc receptor (FcRn) was  
proposed to be involved in the clearance of antibodies from brain to the 
blood (Deane et al., 2005, Cooper et al., 2013), and the design of tetravalent 
bispecific antibodies that  both target the TfR , a brain target, and the FcRn 
were proposed to increase the pharmacological effect of the antibodies 
(Pardridge, 2015).   
 
Figure 2. Schematic illustration of the different transport routes across the brain 
capillary endothelial cells (BCECs). Large proteins are primarily transported by 
either receptor mediated transcytosis (1) or adsorptive mediated transcytosis (2). A 
few small polar molecules, like alcohol, are able to cross the blood-brain barrier by 
paracellular diffusion (3) through the tight junctions. Glucose and amino acids can 
be transported across the BCECs by carrier mediated transcytosis (4). Small 
lipophilic agents can relatively freely cross the lipid membrane through passive 
diffusion (5). However, these are often transported back to the blood by ABC efflux 
transporters such as P-glycoprotein (Pgp) which are abundantly expressed by the 
BCECs. Adapted from (Abbott et al., 2006). 
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1.1.2. Pericytes 
The continuous support of pericytes to the BCECs is essential for proper 
BBB function. Pericytes are polymorphic, elongated, multi-branched mural 
cells, which wrap around the BCECs of the microvasculature. The greater 
the number of pericytes the tighter is the vascular barrier (Shepro and Morel, 
1993). It is estimated that the ratio of pericytes to endothelial cells in CNS is 
1:1-1:3 and 1:10-1:100 in striated muscles (Shepro and Morel, 1993, 
Winkler et al., 2014). Pericytes are clearly involved in the formation and 
maintenance of the impermeability of the BBB during development. 
Furthermore, in functional pericytes deficient (platelet derived growth factor 
receptor beta (Pdgfrb
-/-
)) mice, an increased rate of transcytosis in BCECs 
has been observed (Daneman et al., 2010b). The increased transcytotic rate 
is partly modulated through expression of Mfsd2a in endothelial cells. 
Hence, Mfd2a
-/-
 mice have a leaky BBB and show increased vesicular 
transcytosis. Looking at pericyte deficient mice, a positive correlation 
between Mfsd2a expression in the endothelial cells and the degree of 
pericyte coverage was found, which indicates that pericytes affect the 
vesicular traffic, through the modulation of Mfsd2a expression in BCECs 
(Ben-Zvi et al., 2014). In addition, increased capillary diameter, reduced 
vessel density, and increased permeability were observed in pericyte 
deficient mice (Armulik et al., 2010). A recent study demonstrates that the 
forkhead (Foxf2) transcription factor is specifically expressed in pericytes of 
the brain, and Foxf2
-/-
 knockout mice show vascular defects and failure to 
develop a normal BBB (Reyahi et al., 2015). This supports the finding from 
other studies using Pdgfrb
-/-
 mice as a model for pericyte deficiency. 
The importance of pericytes for maintenance of the BBB is supported by 
in vitro studies as co-culturing BCECs with pericytes enhanced the TEER 
(Al Ahmad et al., 2009, Nakagawa et al., 2009, Daneman et al., 2010b, 
Shimizu et al., 2012). The increased tightness of the barrier was proposed to 
be modulated by pericyte secretion of transforming growth factor β 1(TGFβ-
1) (Dohgu et al., 2005). 
Currently, no individually specific marker has been identified for brain 
pericytes, as they share many markers with smooth muscle cells (SMC) 
located in the walls of arteries and arterioles, thereby leaving some 
observations on pericytes a controversy. Although they are not completely 
specific, some commonly accepted markers for brain pericytes include 
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alpha-smooth muscle actin (α-SMA), chondroitin sulfate proteoglycan NG2, 
PDGFRβ, CD13, and desmin (Armulik et al., 2011). 
Pericytes were suggested to be involved in the regulation of the cerebral 
blood flow, since the stimulation of mice whisker pads resulted in dilation of 
first order capillaries, before dilation of the penetrating arterioles (Hall et al., 
2014). However, another study conclude that pericytes do not regulate 
blood-flow, since what is  referred to as truly cerebral capillary pericytes do 
not contract in vivo (Hill et al., 2015). The opposing results of the two 
studies are probably due to different definition of pericytes, since no single 
marker for the identification of pericytes exists. A schematic illustration of 
the distribution of SMCs and pericytes are shown in figure 3. 
 
Figure 3. Distribution of smooth muscle cells (SMC) and pericytes in the vascular 
wall. Smooth muscle cells are present in the vessel wall in arteries and arterioles. At 
the pre-capillary level, both SMCs and pericytes are probably present but when 
reaching the capillaries it is only pericytes, which are present within the vessel wall. 
PBM: Parenchymal basement membrane, EBM: Endothelial basement membrane, 
BECs: Brain endothelial cells, PVS: Perivascular space. 
Previously, α-SMA was used as a marker for pericyte differentiation, 
locating the α-SMA positive pericytes primarily in arterioles and venules and 
α-SMA negative pericytes in mid-capillaries (Hellstrom et al., 1999). The 
differentiation state of the pericytes is important for regulation of BBB 
integrity in vitro, since α-SMA negative pericytes are more prone to increase 
the TEER value compared to α-SMA positive pericytes (Thanabalasundaram 
et al., 2011, Tigges et al., 2012). TGFβ is able to keep pericytes in their α-
SMA positive state, whereas basic fibroblast growth factor (bFGF) maintains 
pericytes α-SMA negative (Thanabalasundaram et al., 2011). Pericytes lose 
the expression of α-SMA when grown in co-culture with astrocytes and/or 
BCECs, when the medium is supplemented with bFGF (Thomsen et al., 
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2015a). These results indicate that pericytes might be able to change both 
phenotype, from α-SMA positive to α-SMA negative, and function 
depending on their stimulation at the BBB in vivo.  
Increasing evidence also suggests that pericytes can transform into 
multipotent stem cells (Dore-Duffy et al., 2006, Nakagomi et al., 2015). 
Capillary pericytes grown in serum-free medium display changed 
morphology, when growing as non-adherent spheres that express nestin and 
NG2. These spheres could differentiate to cells expressing either marker of 
astrocytes, oligodendrocytes, or neurons primarily in combination with the 
expression of α-SMA (Dore-Duffy et al., 2006).  
It is obvious that the overall potential of these peculiar pericytes has not 
yet been fully elucidated. There is no doubt that pericytes are important for 
the function of the BBB; however, the involvement of pericytic stem cells in 
the brain and their regulation of blood flow are less clear.  
1.1.3. Astrocytes 
Astrocytes are star-shaped glial cells with multiple functions in the CNS. 
They provide physical and metabolic support for neurons, and they are 
crucial for the maintenance of many BBB functions. When grown in co-
culture with BCECs, astrocytes increase the TEER, which has been related 
to communicative secretion to the BCECs (Gaillard et al., 2001, Patabendige 
and Abbott, 2014, Burkhart et al., 2015). Hence, astrocytes can induce TJs 
partly through the secretion of sonic hedge hock, (Wang et al., 2014). Glia 
cell-derived neurotrophic factor (GDNF) also secreted from astrocytes 
contributes to increased TEER and reduced permeability of BCECs (Igarashi 
et al., 1999). Astrocytes also secrete TGFβ1, which upregulates the 
expression of TJ proteins (Merwin et al., 1990, Garcia et al., 2004) and 
increase the expression of the efflux transporter P-glycoprotein (Pgp) in 
BCECs of the fetal and neonatal brain (Baello et al., 2014). Angiopoietin 1 
(Ang-1) and bFGF are also produced by astrocytes and take part in the 
induction of TJ proteins (Lee et al., 2003). 
The astrocytic endfeet, which circumvent the basement membrane of the 
BBB (Fig. 1), have a high expression density of the water channel aquaporin 
4 (AQP4) and the K
+ 
channel Kir4.1. The expression of AQP4 and Kir4.1 is 
regulated by the interaction of astrocytic α-dystroglycan with the basement 
membrane protein agrin (Noell et al., 2011). The coupling with agrin 
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provides evidence that the basement membrane of the BBB is important for 
the interaction between cells of the BBB.  
1.1.4. Vascular basement membrane 
The vascular basement membrane denotes a specialised extracellular matrix 
20-200 nm thick. It consists of a three dimensional network composed of 
proteins from four major glycoprotein families, i.e. laminins, collagen IV 
isoforms, nidogens, and heparan sulphate proteoglycans (HSPG) (Timpl, 
1989, Engelhardt and Sorokin, 2009). In addition, the vascular basement 
membrane is also composed of minor components like secreted protein 
acidic and rich in cysteine (SPARC), fibulin 1 and 2, fibronectin, collagen 
types VIII, XV, XVIII, and thrombospondins 1 and 2 (Hallmann et al., 
2005). The basement membrane is generated by self-assembly by both 
laminins and collagen IV into polymer networks, which are linked together 
through the binding of nidogens and the HSPGs perlecan. Laminin is also 
the primary component connecting the basement membrane to the 
surrounding structures (Yurchenco and Schittny, 1990, Hallmann et al., 
2005, Roberts et al., 2012). 
In CNS large blood vessels the basement membrane consists of two 
principally different entities, an endothelial and a parenchymal basement 
membrane, which can be distinguished by their composition of laminin. 
Hence, the endothelial basement membrane contains laminin α4 and α5, 
whereas the parenchymal basement membrane contains laminin α1 and α2. 
In large vessels penetrating the brain surface, the endothelial and 
parenchymal basement membranes are separated by a perivascular space, 
whereas in smaller blood vessels there is no clear separation between the 
endothelial and parenchymal basement membranes. Thus, the basement 
membrane of small vessels appears as a single basement membrane entity 
and contains both endothelial cell laminins α4 and α5, and laminin α2 
produced by astrocytes, but no laminin α1 as in larger vessels (Sixt et al., 
2001, Hallmann et al., 2005). 
The basement membrane is very important for integration of BCECs and 
other cells of the NVU. Endothelial cells and astrocytes have several 
receptors for basement membrane proteins that act to anchor the cells to their 
respective basement membranes, hence contributing to stability of the BBB 
(Engelhardt and Sorokin, 2009). The basement membrane displays a high 
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capacity for binding of soluble factors such as vascular endothelial growth 
factor (VEGF) and bFGF (Bashkin et al., 1989, Hallmann et al., 2005). Thus, 
the basement membrane is likely to contribute to barrier function.  
In addition, the individual components of the basement membrane have 
different functions. Laminins are cross-shaped and consist of an α-chain in 
combination with both a β-chain and γ-chain. Five α, four β, and three γ 
chains have been identified and these are able to combine and form 18 
different laminin isoforms. The different laminin isoforms are named by 
their chain composition. The biological role of the laminins is largely 
defined through their interaction of the α-chain with cell surface receptors 
(Yousif et al., 2013). The laminins of the vascular basement membrane 
consist  of either α1, α2, α4 or α5 in combination with  β1 and γ1 chains 
composing the following laminin isoforms 111, 211, 411, and 511 
(Hallmann et al., 2005). The importance of different laminin isoforms in the 
brain was supported by the creation of different laminin knockout mice 
models. Deletion of astrocytic laminin α2 cause bleeding in deep regions of 
the murine brain, whereas deletion of endothelial laminin α4 reduce the 
migration of T cells across the BBB in a mouse model of multiple sclerosis. 
Thus, laminins are important for both maintenance of the BBB and for 
defining sites for extravasation of inflammatory cells (Wu et al., 2009, 
Sorokin, 2010, Chen et al., 2013). 
Collagen IV of the vascular basement membrane is a threadlike molecule 
derived from three polypeptide chains [α1(IV)2α2(IV)] (Yurchenco and 
Schittny, 1990). In collagen IV [α1(IV)2α2(IV)] knockout mice, collagen IV 
proved unnecessary for the deposition of basement membrane components 
during early embryonic development. However, the deletion caused 
embryonic lethality due to an impaired stability of the basement membrane 
at later embryonic age (Poschl et al., 2004).  
The heparan sulfate proteoglycan perlecan has a multi-domain protein 
core and three glycosaminoglycan chains at its N-terminus.  Perlecan is 
integrated in the collagen IV/laminin network and important for the 
maintenance of the basement membrane integrity and binding of growth 
factors (Gohring et al., 1998, Roberts et al., 2012). The binding of growth 
factors is primarily through the glycosaminoglycan chains, and perlecan is 
thereby able to modulate the paracrine signalling of the surrounding cells 
(Whitelock et al., 2008). Fibronectin forms a dimer of two almost identical 
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units involved in attachment of cells to other cells or the basement 
membrane  (Tilling et al., 1998). 
In vitro, the basement membrane is also important for barrier properties. 
By growing porcine BCECs on filters coated with either laminin, collagen 
IV, fibronectin or a mixture of one-to-one of these proteins, the TEER was 
significantly increased. The greatest increase in TEER was observed when 
the BCECs were grown on collagen IV, collagen IV/fibronectin, and 
fibronectin/laminin coated inserts (Tilling et al., 1998).  
1.2. In vitro BBB models 
In vitro BBB models have become a valuable tool for the study of the 
cellular interaction at the BBB as outlined in the previous sections, but also 
for investigations of the cellular response of the BBB to different insults. 
The in vitro system allows for mechanistic investigations of the BBB, which 
would otherwise have been virtually impossible to perform in vivo 
(Ogunshola, 2011). 
The in vitro BBB models only resemble the in vivo properties of the BBB 
to some extent. Thus, a thorough characterisation is important before 
investigating any specific responses of the BBB. The BCECs are 
characterised by the complex interconnection through TJs. The in vitro 
BCECs should therefore express these complex TJ proteins and have 
restricted paracellular diffusion. The paracellular pathway can be assessed 
trough the measure of TEER and the apparent permeability coefficient 
(Papp) for different molecules (Reichel et al., 2003). 
Various in vitro BBB models have been developed constituting BCECs 
isolated from human (Siddharthan et al., 2007), porcine ((Patabendige and 
Abbott, 2014, Thomsen et al., 2015a), bovine (Helms and Brodin, 2014), rat 
(Nakagawa et al., 2009, Burkhart et al., 2015), and murine brains (Coisne et 
al., 2005, Shayan et al., 2011).  
Both primary cell cultures and immortalised cell lines have been used to 
construct the in vitro BBB models. The immortalised cell cultures have been 
established after isolation of the endothelial cells, e.g. by conditionally 
immortalisation by introducing the temperature-sensitive simian virus 40 
large T-antigen (Siddharthan et al., 2007). The immortalised cell lines are 
frequently used due to their ease compared to primary cells, which can be 
difficult to isolate, reveals a low yield, and their isolation can be complicated 
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by contamination by other cell types (Ogunshola, 2011). Some of the most 
widely used immortalised brain endothelial cell lines include the Rat Brain 
Endothelial Cell line RBE4, the human brain microvessel endothelial cell 
line hBMEC/D3, and the murine brain endothelial cell line b.End3. 
However, a great disadvantage of using immortalised cell lines is that they 
tend to loose many of their in vivo characteristics like restricted paracellular 
diffusion when grown in culture for multiple passages (Reichel et al., 2003). 
Thus, primary cells will resemble the in vivo situation more, and the results 
obtained from culture of primary cells are more likely to replicate the in vivo 
situation.  
 
Figure 4. Illustration of different in vitro blood-brain barrier (BBB) models using 
the Transwell system. The brain capillary endothelial cells (BCECs) are grown on 
top of the porous filter membranes. The BCECs can be grown in contact or non-
contact co-culture with either pericytes or mixed glial cells. The model which 
resembles the BBB in vivo the most is denoted by the triple-culture consisting of 
BCECs grown on the top of the inserts, pericytes on the back, and mixed glial cells 
in the bottom of the wells. 
One of the largest challenges in the isolation of BCEC is the 
contamination of pericytes. BCECs express the efflux transporter Pgp, and 
are able to survive relative high concentrations of the Pgp substrate 
puromycin. Therefore, treatment of isolated BCECs with puromycin, greatly 
reduces the amount of pericytes (Perriere et al., 2005, Calabria et al., 2006). 
To further enhance the purity of the BCECs, substitution of fetal bovine 
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serum (FBS) with bovine platelet-poor plasma-derived serum (PDS) greatly 
improves BCEC culture purity. The effect of PDS is correlated to the lack of 
platelet-derived growth factor in PDS, which stimulates growth of pericytes 
and smooth muscle cells (Gordon et al., 1991, Calabria et al., 2006).  
The Transwell system is the most commonly used system for the 
construction of in vitro BBB models (Fig. 4). The BCECs are seeded in 
inserts containing a porous filter membrane, which allows for the formation 
of a monolayer and induction of cell polarity. Pericytes or astrocytes are 
subsequently seeded on the back of the filters hence creating either a contact 
co-culture or in the bottom of the wells creating a non-contact co-culture. 
The model, which reassembles the BBB in vivo the most, is denoted by the 
triple-culture that contains BCECs, pericytes, and astrocytes (Ogunshola, 
2011).  
 
Figure 5. Graphical illustration of the apparent permeability coefficient (Papp) to 
mannitol in three different in vitro models. Papp is plotted against the measured 
Transendothelial electrical resistance (TEER) for murine (red), rat (blue) and 
porcine (green) brain capillary endothelial cells. The data are provided with 
acceptance from Study I, Burkhart et al. (2015), and Thomsen et al. (2015).  
Chapter 1. The blood-brain barrier (BBB) 
 
29 
Besides co-culturing the cells of the BBB, the addition of soluble factors 
are beneficial for induction of barrier properties. Increased levels of 
intracellular cyclic adenosine monophosphate (cAMP) increase the TEER. 
This can be obtained by the addition of a combination of a cAMP analogue 
(CPT-cAMP) and a phosphodiesterase inhibitor (Ro 20-1724) (Rubin et al., 
1991, Rist et al., 1997). The increased cAMP level cause increased 
phosphorylation of claudin-5 which leads to increased caludin-5 at the 
contact points between BCECs, thereby contributing to the increase in TEER 
(Soma et al., 2004). Like increased levels of cAMP, the addition of 
physiological levels of hydrocortisone (550 nM) also increases TEER 
(Hoheisel et al., 1998, Forster et al., 2005).  
TEER varies greatly among the species from where the BCECs are 
isolated. Rat BCECs usually have higher TEER than their murine 
counterpart (Shayan et al., 2011, Burkhart et al., 2015), and the TEER 
obtained by BCECs from both porcine and bovine are much higher than 
those obtained from rodents (Helms and Brodin, 2014, Patabendige and 
Abbott, 2014, Thomsen et al., 2015a). Although higher TEER values persist 
in porcine and bovine models, there are good indications that the rodent 
models do not need TEER values of that magnitude to obtain a similar low 
permeability to mannitol. To obtain a Papp for mannitol below 5*10
-6
 cm/s, 
the TEER for rat BCECs should be above ~150 Ω*cm2 (Burkhart et al., 
2015), for porcine BCECs above ~600 Ω*cm2 (Thomsen et al., 2015a), and 
murine BCECs above ~130 Ω*cm2 (Study I) (Fig. 5).  
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Chapter 2. Neurodegeneration with 
inflammation 
As outlined in the previous sections the complex interaction between the 
BCECs, pericytes, astrocytes, and the basement membrane is crucial for 
proper BBB function. Conditions with neurodegeneration like Alzheimer’s 
disease, Parkinson’s disease and multiple sclerosis are accompanied by 
inflammation and perturbation of the BBB (Jansson et al., 2014, Monson et 
al., 2014). Some of the characteristic features associated with inflammation 
in CNS include activation of microglia cells and astrocytes (reactive gliosis) 
with a subsequent release of various inflammatory mediators that lead to 
changes of the brain microenvironment associated with increased 
permeability of the BBB and migration of inflammatory cells into the CNS 
(Vivekanantham et al., 2015).   
2.1. Microgliosis 
Microglial cells are resident macrophages of the CNS that act as the first line 
of defence to brain insults (Alliot et al., 1999, Rezai-Zadeh et al., 2009). 
Microglia expresses different pattern recognition receptors (PRRs) through 
which they detect changes of the brain microenvironment. The receptors 
recognise pathogen-associated molecular pattern (PAMPs) from 
microorganisms or damage-associated molecular patterns (DAMPs), which 
are endogenous components released by stressed, dying, or dead neurons. 
These receptors include Toll-like receptors (TLRs), RIG-1 like receptors, 
Nod-like receptors, and macrophage antigen complex 1 (MAC1/CD11b) the 
latter also functioning as an adhesion molecule (Chen et al., 2015).  
Compared to resting microglia that have small cell bodies and thin 
ramified processes, activated microglial cells change morphology exhibiting 
enlarged cell body and irregular shape (Qin et al., 2013). The activated 
microglia release various pro-inflammatory mediators like cytokines, 
prostaglandins, chemokines, reactive oxygen species (ROS), and reactive 
nitrogen species (RNS), which amplify the inflammatory response, and 
exacerbate the neurodegeneration (Chen et al., 2015). Lipopolysaccharide 
(LPS) activates microglia cells through the interaction with CD11b, which 
leads to increased expression of NADPH-oxidase 2 (NOX2) and 
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subsequently increased production of ROS (Fig. 6). The increased 
production of ROS is correlated to the maintenance of the 
neuroinflammatory process (Pei et al., 2007, Qin et al., 2013). The pro-
inflammatory cytokines released by activated microglia cells also include 
tumour necrosis factor alpha (TNF-α) and different isoforms of interleukin-1 
(IL-1β, IL-1α). In vitro BCECs have increased permeability to sodium-
fluorescein in response to microglia produced TNF-α, thereby correlating the 
production of TNFα to BBB dysfunction (Nishioku et al., 2010). α-synuclein 
binding to TLR4 on microglia cells results in translocation of nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) to the nucleus and 
subsequently expression and secretion of TNFα, IL-6 and CXCL1 (Fellner et 
al., 2013). Furthermore, the production of IL-1 by microglial cells are 
correlated with astrocyte proliferation (Giulian et al., 1986). Activated 
microglia also secrete a wide variety of chemokines involved in the cellular 
migration and communication (Tambuyzer et al., 2009).  
2.2. Astrogliosis 
Astrocytes are important for maintaining brain homeostasis e.g. through the 
support of the BBB function and regulation of the extracellular balance of 
ions and neurotransmitters. Reactive astrogliosis refers to the process 
whereby astrocytes become activated in response to different insults of the 
CNS such as neurodegeneration, infections, and trauma (Sofroniew, 2009). 
The activated astrocytes have hypertrophic cellular processes and increased 
expression of intermediate filaments, including glial fibrillary acidic protein 
(GFAP) (Pekny and Nilsson, 2005). The response of the activated astrocytes 
depends on the underlying cause varying from beneficial to harmful 
(Zamanian et al., 2012, Sofroniew, 2015). In severe astrogliosis, the 
astrocytes can proliferate and form a scar on the border between the healthy 
and damaged brain tissue (Fig. 6) (Sofroniew, 2009).   
Astrocytes are important for maintaining a low extracellular level of 
glutamate and blockage of the astrocyte glutamate transports GLAST and 
GLT-1 leads to increased extracellular glutamate levels and subsequent 
excitotoxicity induced neurodegeneration (Rothstein et al., 1996). Thus, it 
has been proposed that reactive astrogliosis are valuable for not intensifying 
excitotoxic-induced neurodegeneration (Sofroniew, 2009).  
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Figure 6. Simplified illustration of the cellular response to neurodegeneration. 
Various insults can lead to neuronal (N) damage causing the release of damage-
associated molecular patterns (DAMPs). The DAMPs activates the microglial cells 
(M) through binding to the pattern recognition receptors such as toll-like receptor 
(TLR) and CD11b. The microglial cells then release various cytokines, chemokines, 
and reactive oxygen species (ROS), which contributes to neuronal damage and 
activate surrounding cells, such as the pericyte (P), astrocytes (A) and brain 
endothelial cells (BECs).  The endothelial cells upregulate their expression of cell 
adhesion molecules such as vascular cell adhesion molecule 1 (VCAM1) and 
intercellular adhesion molecule 1 (ICAM1) and release chemokines, which leads to 
the infiltration of leucocytes (L). The infiltrating leucocytes differentiate in the 
perivascular space (PVS) to brain macrophages (bM), which contribute to the 
neuroinflammatory process. 
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In vitro studies using primary cultures reveal that astrocytes in response 
to common pro-inflammatory cytokines (TNFα, IL-1β) secrete chemokines 
like CCL2, CCL7, and CXCL1 (Thompson and Van Eldik, 2009, Fellner et 
al., 2013). These results were confirmed in vivo where intrahippocampal 
injection of TNFα or IL-1β increased the production of CCL2 and CXCL1 in 
the astrocytes. This increased production of chemokines in the inflamed 
brain lead to recruitment of inflammatory cells to the brain parenchyma from 
the periphery (Thompson and Van Eldik, 2009). After in vitro LPS exposure, 
astrocytes also secrete pro-inflammatory cytokines, such as IL-1β, TNF-α, 
and IL-6 which can aggravate the inflammatory response (Li et al., 2015). 
2.3. Change of the BBB  
2.3.1. Brain capillary endothelial cells (BCECs) 
As a response to chronic neurodegeneration with inflammation the BCECs 
have changed permeability. Increased permeability to the plasma protein-
binding dye Evans Blue and increased deposition of major plasma proteins 
like immunoglobin G (IgG) and fibrinogen were observed in brains of 
transgenic mouse models of Alzheimer’s disease (Dickstein et al., 2006, Paul 
et al., 2007, Ryu and McLarnon, 2009, Biron et al., 2011, Merlini et al., 
2011). Other major features related to changes in the vascular integrity in 
Alzheimer’s disease are increased capillary density due to neoangiogenesis 
(Patel et al., 2011), hypervascularity (Biron et al., 2011), and disruption of 
tight junctions between BCECs (Marco and Skaper, 2006, Liu et al., 2011). 
Identical changes are seen in multiple sclerosis in where an altered 
expression of tight junction and adherence junction proteins are observed in 
the lesion areas in conjunction with astrogliosis and leakage of serum 
proteins (Kirk et al., 2003, Alvarez et al., 2011). Also, in Parkinson’s 
disease, increased permeability of the BBB has been observed (Sarkar et al., 
2014). 
Some of the changes observed in such distinct diseases are possibly 
related to the common underlying neuroinflammation associated to the 
neurodegeneration. The BCECs respond to the increased production of 
cytokines and chemokines by increasing the expression of cell-adhesion 
molecules thereby promoting the infiltration of leucocytes to the brain (Fig. 
6), which is believed to contribute to the neuroinflammation and BBB 
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changes (Brown et al., 1994, Sorokin, 2010, Larochelle et al., 2011). The 
primary site for leucocyte trafficking into the brain is at the post-capillary 
venules (Sorokin, 2010).  
In brain regions with neurodegeneration and inflammation an increase 
deposition of iron is also observed (Connor et al., 1992, Bartzokis et al., 
1999, LeVine et al., 2013). The increase in iron load is proposed to relate to 
infiltration of iron-containing leucocytes in particularly monocytes. The 
monocytes transform to brain macrophages, engulfing cellular debris, and 
when they die out, their iron-content is released, which further contributes to 
neurodegeneration and production of ROS (Andersen et al., 2014).  
2.3.2. Pericytes 
Pericytes are important for development and maintenance of the BBB. The 
embedding inside the basement membrane makes the pericyte an obvious 
player in brain inflammation. Like other cells of the brain, the pericytes are 
able to synthesise chemokines such as CCL2, CXCL9, and CXCL10 and in 
response to pro-inflammatory stimuli with LPS or cytokines like TNFα, IL-
1β and interferon gamma (IFNγ) (Jansson et al., 2014). The stimulation of 
pericytes with TNFα also leads to increased production of MMP9 and the 
cytokines macrophage inflammatory protein (MIP)-1α and IL-6 (Takata et 
al., 2011, Matsumoto et al., 2014). TNFα stimulated pericytes are also strong 
activators of microglia cells, which increase their expression of IL-1β and 
inducible nitric oxide synthase (iNOS) adding to the inflammatory process 
(Matsumoto et al., 2014). In a mouse model of multiple sclerosis, pericytes 
change their expression of integrins, hence promoting the proliferation and 
migration of pericytes. An identical change in integrin expression is 
observed, when pericytes are stimulated with TNFα in vitro (Tigges et al., 
2013).  
Brain vessels of Alzheimer’s disease mice have decreased pericyte 
coverage compared to the wild type, and the remaining pericytes have 
elongated and hypertrophic processes (Park et al., 2013). Congruent to 
observations in Tg2576 mice, the number of pericytes in autopsies from 
Alzheimer patients are decreased, and their surface coverage of brain 
capillaries reduced (Baloyannis and Baloyannis, 2012, Sengillo et al., 2013). 
Morphologically, the remaining pericytes exhibit increased number of 
pinocytic vesicles, large lipid granules, and mitochondrial alterations, 
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suggesting, that their functionality is compromised  (Baloyannis and 
Baloyannis, 2012). Furthermore, a tight correlation between reduced pericyte 
coverage and extravascular IgG and fibrin deposition have been observed in 
Alzheimer’s disease subjects (Sengillo et al., 2013), which strongly supports 
the notion of pericytes being important for maintaining the integrity of the 
BBB. It should not be overlooked, however, that opposing results were 
reported. Hence, investigations on post mortem brain samples from 
Alzheimer’s and Parkinson’s patients revealed no difference in degenerative 
pericytes compared to control specimens (Farkas et al., 2000).  
2.3.3. Astrocytes 
The support of the astrocytic endfeet is important for maintaining the 
functions of the BBB. Thus, retraction of the endfeet can cause impairment 
of the BBB and lead to increased permeability. Retraction of astrocyte 
endfeet has been observed in a mouse model of Alzheimer’s disease 
especially in brain areas affected by cerebral amyloid angiopathy (CAA) 
(Merlini et al., 2011). CAA is a condition where amyloid β (Aβ) are being 
deposited in the vessel wall and is correlated to approximately 80 % of 
Alzheimer’s disease cases (Deane and Zlokovic, 2007). In addition, a major 
hallmark in Alzheimer’s disease is the formation of intracellular 
neurofibrillary tangles, which are composed of hyperphosphorylated tau 
protein. The cerebral response to injected mutant tauP301L in mice after 10 
and 21 days is the presence of swollen astrocyte endfeet and increased 
thickening of the capillary vessel walls (Jaworski et al., 2011). Also, in a 
mouse model of multiple sclerosis retraction of astrocytes endfeet has been 
observed. The retraction was correlated to a decreased expression of β 
dystroglycan which is involved in attachment of the endfeet to the 
vasculature through the interaction with vascular laminin (Agrawal et al., 
2006). Retraction of astrocyte endfeet is also observed, in post-mortem brain 
specimens from patients with multiple sclerosis (Claudio et al., 1995).  
2.3.4. Vascular basement membrane 
As previously described, the basement membrane is important for proper 
function of the BBB, and changes of the basement membrane are observed 
in response to neurodegeneration with inflammation. To some extent this is 
related to the release of cytokines and proteases by invading inflammatory 
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cells. The secretion of matrix metalloproteinases (MMPs) is correlated to the 
remodelling of the basement membrane, and the resulting cleaved protein 
fragments are believed to affect both activity and function  of infiltrating and 
resident cells (Sorokin, 2010).  
MMPs belong to a family of calcium dependent and zinc containing 
endopeptidases. They are produced in a latent form and contain multiple 
regions including a N-terminal signal peptide, a propeptide responsible for 
maintaining MMP in a latent state and C-terminal hemopexin-like domain. 
The latter is essential for the recognition of MMPs by the tissue inhibitor of 
matalloproteinases (TIMPs). Different enzymes or free radicals can activate 
MMPs through direct cleavage of the prodomain or by  a cysteine switch 
mechanism (Brkic et al., 2015).  The function of MMPs is regulated on 
multiple levels. Increased MMP transcription is seen in response to 
proinflammatory cytokines, and then MMP can be activated by removal of 
the prodomain, or inhibited by TIMP recognition (Loffek et al., 2011). 
In Alzheimer’s disease, three distinct changes in the basement membrane 
are seen, i.e. deposition of amyloid beta (Aβ) in the vessel wall also referred 
to as CAA, basement membrane thickening, and changes in the protein 
composition (Deane and Zlokovic, 2007). The cause of the Aβ deposition in 
the vessel wall remains unknown, but it is linked to both a decreased 
clearance of Aβ across the BBB and thickening of the basement membrane 
(Okoye and Watanabe, 1982, Deane and Zlokovic, 2007). Basement 
membrane thickening is observed in the capillaries of Alzheimer’s disease 
patients (Mancardi et al., 1980, Zarow et al., 1997, Farkas et al., 2000). The 
cause of the basement membrane thickening is not fully elaborated just like 
the fact that the cell-types responsible for its thickening are unknown. 
Astrocytes are suggested to be mainly responsible for the thickening, since 
immune electron microscopy revealed that only the parenchymal basement 
membrane was affected (Zarow et al., 1997). Basement membrane 
thickening is also seen in post mortem brain samples from Parkinson’s 
disease patients (Farkas et al., 2000), and in multiple sclerosis increased 
deposition of fibrin and collagen are seen in post mortem specimens 
(Claudio et al., 1995).  
The distribution of individual basement membrane proteins is altered in 
Alzheimer’s disease. The amount of collagen IV and laminin decrease and 
the amount of fibronectin and perlecan conversely increase in brains of an 
aged Alzheimer’s mouse model (Hawkes et al., 2013). The changes in 
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basement membrane composition could accelerate the accumulation of Aβ, 
since perlecan accelerates Aβ fibril formation and stabilise newly formed 
fibrils (Castillo et al., 1997). The pericyte is also linked to the changes in the 
basement membrane composition observed in Alzheimer’s disease. Human 
pericytes cultured in the presence of Aβ increase their concentration of both 
mRNA and protein concentration of agrin and glypican-1 (Timmer et al., 
2009). Increased soluble agrin has also been observed in the vasculature in 
human autopsies of late stage Alzheimer’s disease, where it associates with 
Aβ-plaques and the vascular basement membrane (Berzin et al., 2000).  
 39 
Chapter 3. Thesis objectives 
The complex interaction of the components of NVU are of outermost 
importance for proper function of the BBB, and hence also for maintaining a 
healthy brain microenvironment. The objective of the thesis has therefore 
been to obtain a more thorough understanding of the BBB in health and 
disease, using an in vitro murine BBB model, and an in vivo model for 
chronic neurodegeneration. 
 
For the investigation of the overall objective of the thesis, four separate 
experimental studies have been generated each with separate aims. Study I 
and II are related to the normal BBB using a murine in vitro BBB model, 
whereas consequences of neurodegeneration with inflammation are 
investigated in study III and IV in a rat model of neurodegeneration with 
inflammation.  
 
Study I: To establish and characterise four different murine in vitro BBB 
models using primary murine brain capillary endothelial cells (mBCECs), 
pericytes and mixed glial cells. Furthermore, the contribution of the 
mBCECs to the synthesis of basement membrane proteins is investigated.  
  
Study II: To investigate the expression of the neonatal Fc Receptor (FcRn) 
in the in vitro BBB model with mBCECs grown in co-culture with mixed 
glial cells established in study I.  
 
Study III: To investigate inflammatory response and the handling of iron in 
an experimental in vivo model of neurodegeneration with inflammation.  
 
Study IV: To investigate the state of the BBB in the same experimental in 
vivo model of neurodegeneration with inflammation as established in study 
III.  
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Chapter 4. Methods and Results 
4.1. Study I 
Expression and deposition of basement membrane proteins by brain 
capillary endothelial cells in a primary murine model of the blood-brain 
barrier 
Maj Schneider Thomsen, Svend Birkelund, Annette Burkhart, Allan Stensballe and 
Torben Moos
 
Manuscript in preparation 
Abstract 
Background: Many cerebral conditions with neurodegeneration, e.g.  Alzheimer’s 
disease, Parkinson’s disease and multiple sclerosis are accompanied by 
inflammation and changes in the vascular basement membrane. The changes of the 
basement membrane are thought to contribute to structural changes of the blood-
brain barrier (BBB). Primary cell models of the cerebral vasculature are valuable 
tools for studying various insults to the BBB. The aim of the present study has been 
to characterise four different in vitro setups of the murine BBB and investigate the 
expression of basement membrane proteins by the murine brain capillary endothelial 
cells (mBCECs). 
Methods: Primary mBCECs and pericytes were isolated from adult mouse brains. 
Mixed glial cells (mainly astrocytes and microglia) were prepared from cerebral 
cortices of newborn mice. The mBCECs were grown in four setups: in mono-
culture, and in co-culture with pericytes, mixed glial cells, or both. The integrity of 
the BBB models was evaluated by measures of transendothelial electrical resistance 
(TEER) and passive permeability to mannitol. To study the expression of basement 
membrane proteins RT-qPCR, mass spectrometry and immunofluorescent labelling 
were used. 
Results: The four different murine BBB model setups were developed and 
characterised. Co-culturing of mBCECs with pericytes, mixed glial cells, or both 
significantly increased the TEER compared to the mono-culture, and a low passive 
permeability was correlated with high TEER. The mBCECs were found to express 
major basement membrane proteins in vitro and the expression of laminin α5 and 
collagen IV α1 was regulated by the culture conditions.  
Conclusion: Here we present a model of the murine BBB with defined BBB 
properties: high TEER, low permeability to mannitol and expression of endothelial 
markers (claudin-5 and ZO1). Furthermore, the obtained data reveal that mBCECs 
synthesise major basement proteins in vitro.  
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4.2. Study II 
Characterisation of the expression of the neonatal Fc receptor by 
murine brain capillary endothelial cells 
 
Maj Schneider Thomsen, Svend Birkelund, Allan Stensballe, Torben Moos 
 
Manuscript in preparation 
Abstract 
Background: The neonatal Fc receptor (FcRn) is presumed to be involved in the 
clearance of antibodies from the brain parenchyma to the blood and this mechanism 
can be an important function for immunotherapy delivery to the brain. The usage of 
in vitro blood-brain barrier (BBB) models has become a valuable tool for the study 
of various functions of the BBB, such as protein transport and the response of the 
BBB to different stimuli. The aim of the present study was, therefore, to characterise 
a murine in vitro BBB model for the expression of FcRn. 
Methods: Primary cultures of murine brain capillary endothelial cells (mBCECs) 
were grown in co-culture with mixed glial cells and analysed for the expression of 
FcRn using a polyclonal (M-255) and a monoclonal (1G3) antibody.  
Results and conclusions: The immunolabeling with M-255 and 1G3 of mBCECs in 
vitro was negative, however, after additional analysis it was concluded that FcRn is 
indeed expressed albeit at low levels by the mBCECs as determined with RT-qPCR 
and mass spectrometry. Furthermore, transfection with mouse FcRn of mBCECs 
showed detectable amount of FcRn in the cytoplasm.  
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4.3. Study III 
Neurodegeneration with inflammation is accompanied by accumulation 
of iron in microglia and neurons 
Maj Schneider Thomsen, Michelle Vandborg Andersen, Pia Rægaard 
Christoffersen, Malene Duedal Jensen, Jacek Lichota, Torben Moos 
 
Published in Neurobiology of Disease, Volume 81, September 2015, Pages 108-118 
The manuscript can be seen in appendix A. 
Abstract 
Chronic inflammation in the substantia nigra (SN) accompanies conditions with 
progressive neurodegeneration. This inflammatory process contributes to gradual 
iron deposition that may catalyze formation of free-radical mediated damage, hence 
exacerbating the neurodegeneration. This study examined proteins related to iron-
storage (ferritin) and iron-export (ferroportin) (aka metal transporter protein 
1,MTP1) in a model of neurodegeneration. Ibotenic acid injected stereotactically 
into the striatum leads to loss of GABAergic neurons projecting to SN pars 
reticulata (SNpr), which subsequently leads to excitotoxicity in the SNpr as neurons 
here become vulnerable to their additional glutamatergic projections from the 
subthalamic nucleus. This imbalance between glutamate and GABA eventually led 
to progressive shrinkage of the SNpr and neuronal loss. Neuronal cell death was 
accompanied by chronic inflammation as revealed by the presence of cells 
expressing ED1 and CD11b in the SNpr and the adjacent white matter mainly 
denoted by the crus cerebri. The SNpr also exhibited changes in iron metabolism 
seen as a marked accumulation of inflammatory cells containing ferric iron and 
ferritin with morphology corresponding to macrophages and microglia. Ferritin was 
detected in neurons of the lesioned SNpr in contrast to the non-injected side. 
Compared to non-injected rats, surviving neurons of the SNpr expressed ferroportin 
at unchanged level. Analyses of dissected SNpr using RT-qPCR showed a rise in 
ferritin-H and -L transcripts with increasing age but no change was observed in the 
lesioned side compared to the non-lesioned side, indicating that the increased 
expression of ferritin in the lesioned side occurred at the post-transcriptional level. 
Hepcidin transcripts were higher in the lesioned side in contrast to ferroportin 
mRNA that remained unaltered. The continuous entry of iron-containing 
inflammatory cells into the degenerating SNpr and their subsequent demise is 
probably responsible for iron donation in neurodegeneration. This is accompanied 
by only a slight increase in neuronal ferritin and not ferroportin, which suggests 
that the iron-containing debris of dying inflammatory cells and degenerating 
neurons gets scavenged by invading macrophages and activated microglia to 
prevent an increase in neuronal iron.   
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4.4. Study IV 
The neurovascular unit contributes to modulation in the expression of 
extracellular matrix proteins and adhesion molecules in an experimental 
model of neurodegeneration with inflammation  
Maj Schneider Thomsen, Annette Burkhart Larsen, Torben Moos 
Manuscript in preparation 
Abstract 
Introduction: The blood-brain barrier (BBB) represents the interface between the 
blood and brain parenchyma, and is important for ensuring sufficient nutrient 
transport and for maintaining brain homeostasis. Many conditions with 
neurodegeneration and inflammation are accompanied by changes of the BBB, 
including increased BBB permeability and changes of the vascular basement 
membrane. We have previously in an experimental model of neurodegeneration 
shown that excitotoxic-induced neurodegeneration in substantia nigra pars reticulata 
(SNpr) was accompanied by activation of microglial cells and infiltration of 
inflammatory cells. We therefore aimed to investigate if the neurodegeneration with 
inflammation is associated with changes of the BBB.  
Method: The model of neurodegeneration with inflammation was created by 
stereotactical injection of ibotenic acid into the striatum, which subsequently results 
in excitoxicity in SNpr. We examined the BBB permeability by immunolabeling of 
endogenous albumin, and injection of green fluorescent liposomes. The changes of 
the basement membrane and adhesion molecules were investigated using a PCR 
array for 84 different genes. Subsequently, nine of these genes were chosen for 
additional RT-qPCR analysis (Fn1, Col6a1, Col8a1, Spp1, Ctgf, Icam1, Cdh1, 
Mmp3, Timp1). To further investigate the response of BBB to inflammation, an in 
vitro BBB model containing primary rat brain capillary endothelial cells (rBCECs), 
pericytes and astrocytes was exposed to lipopolysaccharide (LPS) and investigated 
for the expression of most of the genes analysed in the in vivo model.  
Results/conclusion: Our findings indicate that in response to the neurodegeneration 
with inflammation increased BBB permeability and changes in the expression of the 
basement membrane protein collagen IV can be observed. Also a large increase in 
Icam1 and Timp1 are observed both in the model of neurodegeneration with 
inflammation and in vitro in response to the exposure to LPS. In vitro the increased 
expression of Icam1 was seen in rBCECs and astrocytes, and increased expression 
of TIMP1 was seen in pericytes and astrocytes suggesting that these cells are at least 
partly responsible for the increased expression of Icam1 and Timp1 seen in vivo in 
response to excitotoxic-induced neuronal death in SNpr.  
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Chapter 5. Discussion 
The first part (study I and II) of this thesis was related to the BBB in normal 
physiological conditions. The main objective of study I was to establish a 
model of the murine BBB using primary mBCECs, pericytes, and mixed 
glial cells, and to investigate the contribution of the mBCECs to the 
synthesis of basement membrane proteins. Four types of BBB models were 
created consisting of mBCECs grown in mono-culture, in co-culture with 
pericytes, or mixed glial cells, and in triple-culture with both pericytes and 
mixed glial cells. Using the co-culture model with mBCECs and mixed glial 
cells established in study I, the expression of the FcRn was investigated in 
study II. 
The second part of the thesis (study III and IV) investigated the 
consequences of chronic neurodegeneration with inflammation. In study III, 
the inflammatory response and handling of iron were investigated in a rat 
model with neurodegeneration caused by excitotoxicity in SNpr. Using the 
same model, the state of the BBB and gene expression of basement 
membrane and adhesion molecules were investigated in study IV.  
5.1. Blood-brain barrier models 
In study I, four different murine in vitro BBB setups were established and 
characterised. The mBCECs and pericytes were successfully isolated from 
the brains of 6 to 10 weeks old mice. The mBCECs were identified by 
immunolabeling of the tight junction proteins claudin-5 and ZO1. 
Furthermore, high purity of the mBCEC cultures was obtained by growing 
the isolated cells in specialised growth medium with puromycin. The 
mBCECs have high expression of the efflux transporter Pgp. Thus, they are 
able to survive relative high amounts of puromycin (Perriere et al., 2005, 
Calabria et al., 2006).  
The differentiation state of the pericytes is important for their capabilities 
of inducing BBB integrity (Thanabalasundaram et al., 2011, Yao et al., 
2014). The pericytes were identified by immunolabeling of α-SMA and 
PDGFRβ. The pericyte culture contained pericytes, which were both α-SMA 
and PDGFRβ positive, and pericytes with a more disorganised staining 
pattern with only a weak expression  α-SMA (from now referred to as α-
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SMA negative). The isolated pericytes were grown in basic growth medium 
until confluent, where they were passaged to filters and the medium changed 
to mBCEC medium with bFGF. After 4 days, the mBCECs were seeded on 
top of the filters. The pericytes were therefore immunolabeled after they had 
been grown 4 days in medium with bFGF. The addition of bFGF has been 
proposed to maintain the pericytes in an α-SMA negative state, which is the 
main type of pericytes responsible for the induction of barrier properties 
(Thanabalasundaram et al., 2011). The pericytes were equally as potent as 
the mixed glial cell culture to induce high TEER of the mBCECs, which 
indicates that the pericyte culture contained a sufficient amount of α-SMA 
negative pericytes. The pericytes could also change phenotype during the co-
culturing with mBCECs, since it was previously shown that porcine 
pericytes lose their α-SMA expression after co-culturing with porcine 
BCECs (Thomsen et al., 2015a).  
The mixed glial cells were isolated from brain cortices of new-born mice. 
The culture contained primarily astrocytes and some microglial cells 
identified by immunolabeling of GFAP and CD11b, respectively. The 
microglial cells grow on top of the astrocytes (Schildge et al., 2013), and to 
diminish the amount of microglia  the cultures were vigorously washed in 
PBS. For the induction of BBB properties, the presence of microglia cells 
and possible oligodendrocytes are acceptable, since these cell types are also 
in close proximity to the BBB in vivo. However, when specific functions of 
astrocytes are investigated, the presence of other glial cells can become an 
obstacle. Therefore, to obtain enriched astrocyte cultures different 
approaches exist. Shaking of the of the culture on an orbital shaker or adding 
of the antimitotic toxin cytosine β-D-arabinofuranoside (Ara-C) and the 
lysosomotropic agent L-leucine methyl ester are methods, which have been 
developed to obtain enriched astrocytes cultures (Hamby et al., 2006, 
Schildge et al., 2013). 
In the present study, a murine BBB model was developed since most 
genetic modified animal are mice. Thus, for the investigation of genetic 
modified mouse models the construction of a murine BBB model are of 
great value for future investigations of conditions that would otherwise have 
been virtually impossible to study in vivo. However, it should also be noted 
that the yield of BCECs isolated from mouse brain are less than the yield 
from both rat and porcine brains, based on the experience from our lab. 
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Thus, the creation of primary murine BBB models is more costly than those 
models created of BCECs isolated from rat and porcine brains. 
5.2. IgG transport across the BBB 
Data indicates that the FcRn are involved in the clearance of the off IgG 
from brain to the blood (Deane et al., 2005, Cooper et al., 2013). In the 
search for new treatment strategies for treatment of neurodegenerative 
diseases, much research have been carried out in order to develop bispecific 
antibodies, which are able to bind both to the TfR, whereby the antibodies 
can be shuttled across the BBB, while simultaneously binding or neutralising 
a target of the diseased brain tissue (Yu et al., 2011, Yu et al., 2014). To 
further increase the pharmacological effect of the antibodies, the design of 
tetravalent bispecific antibodies which targets the TfR, a brain target, and 
FcRn has been proposed (Pardridge, 2015). The initial purpose of study II 
was therefore to investigate the involvement of FcRn IgG transport across 
mBCECs in vitro. This was, however, complicated by problems in 
identifying the receptor. This is a good example of the importance of proper 
characterisation of the model before initiation of the investigations (Reichel 
et al., 2003). The expression of FcRn in mBCECs was confirmed with RT-
qPCR and mass spectrometry and immunolabeling of mouse brain tissue. 
However, we only observed immunolabeling of FcRn in few capillary 
structures, which questions the biological relevance of designing tetravalent 
bispecific antibodies (Pardridge, 2015). Thus, the involvement of FcRn in 
the efflux of IgG still remains a dispute.  
5.3. Model of neurodegeneration with inflammation 
In study III and IV, a model of neurodegeneration with inflammation was 
created by stereotactic injection of the glutamate receptor agonist ibotenic 
acid into striatum, leading to cell death among the GABAergic neurons 
projecting to substantia nigra pars reticulata (SNpr). Subsequently, this 
results in an overstimulation of the neurons in SNpr from the glutamate 
projections from nucleus subthalamicus (Sastry and Arendash, 1995). 
Glutamate is a major excitatory neurotransmitter in the CNS, and the 
imbalance between glutamate and GABA will therefore eventually result in 
neurodegeneration in SNpr caused by excitotoxicity. The neurodegeneration 
and accompanying neuroinflammation is thereby being created at a remote 
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site from the initial injection site. The relevance of creating a model with 
excitotoxic-induced neurodegeneration is supported by the fact that 
conditions with chronic neurodegeneration such as Parkinson’s disease and 
Alzheimer’s disease also are accompanied by glutamate mediated 
neurotoxicity (Mehta et al., 2013). The glutamate mediated neurotoxicity is 
believed to be mediated through two processes. The first part cause acute 
swelling of the cell body and peripheral processes through opening of cation 
channels followed by a slowly evolving degeneration of the neurons, 
possibly mediated by the influx of Ca
2+
 (Koh and Choi, 1991, Hynd et al., 
2004).  
In study IV the in vivo studies were supported by in vitro investigations 
of the response of the BBB to stimulation with LPS. LPS is a major part of 
the wall of gram-negative bacteria, and it can be used to create an 
inflammatory response both in vivo and in vitro. LPS was added to the 
bottom chamber, and the cells were exposed to LPS for 17 hours as 
previously described (Coisne et al., 2005). In response to LPS, the TEER 
significantly decreased compared to the control cells. The decrease in TEER 
was not accompanied by significant change in claudin-5 expression. This is 
supported by another study investigating the in vitro response of the BBB to 
LPS. Immunolabeling of claudin-5 revealed no change in organisation 
oppositely, to both organisation of ZO1 and occludin which was altered in 
response to LPS exposure (Banks et al., 2015). This indicates that the 
decreased TEER could be a result of changed expression of ZO1 and 
occludin, and not claudin-5.  
5.4. Evaluation of blood-brain barrier permeability 
In study IV, the immunolabeling of albumin on post-surgery day 91 revealed 
large patches of immunoreaction in the lesioned side and no immunoreaction 
in the non-lesioned side. This indicates that the BBB has been compromised 
during the 91 days post-surgery. To evaluate BBB permeability on post-
surgery day 28 and 91, 75 nm green fluorescent liposomes were injected two 
hours prior to the termination of the rats. No apparent permeability was 
observed and the detection of the green fluorescent liposomes was 
complicated by autoflourescence within the brain tissue.  
BCECs are non-fenestrated, thus, the transcellular permeability is low 
and only small lipophilic molecules <1nm in size are able to pass through the 
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BCECs (Sarin, 2010). However, the transcellular passaging is further 
complicated by the expression of efflux transporters by the BCECs, which 
transport crossing molecules back to the blood (Abbott et al., 2010). 
Furthermore, the BCECs have low paracellular transport due to the complex 
interaction of the TJ proteins (Wolburg et al., 2009, Abbott et al., 2010). 
Increased paracellular permeability can be caused by changes in the TJ 
proteins, whereby small intercellular gaps are created, allowing the passage 
across the BBB of plasma proteins such as albumin and infiltration of 
leucocytes (Stamatovic et al., 2008). The interaction and distribution of the 
TJ proteins are affected by their phosphorylation state (Kago et al., 2006, 
Stamatovic et al., 2006).  
Depending on the underlying pathology, different factors are involved in 
the changed permeability of the BBB. As shown in both the study III and IV, 
the neurodegeneration caused by excitotoxicity in SNpr was accompanied by 
activation of microglia, astrocytes and infiltration of inflammatory cells. 
Thus, the alteration of the BBB is possible related to the inflammatory 
response to the neurodegeneration. The activated glial cells and infiltrating 
inflammatory cells secrete multiple pro-inflammatory mediators (Fig. 6), 
which can affect the permeability of the BBB (Thompson and Van Eldik, 
2009, Nishioku et al., 2010, Fellner et al., 2013).  
Different approaches exist to evaluate BBB permeability. Liu et al. 
(2015) investigated the BBB permeability in three different mouse models 
(Middle Cerebral Artery Occlusion (MCAO), LPS, and cold injury) by 
injection of Evans blue (Liu et al., 2015). Evans blue has high affinity for 
albumin and can be visualised by excitation with a laser. Thus, basically 
detection of Evans blue equals the detection of albumin (Radu and Chernoff, 
2013). The greatest leakage was observed after MCAO and was 
accompanied by decrease expression of claudin-5 and VE-cadherin. Banks et 
al. (2015) also investigated the BBB permeability after LPS induced 
inflammation. For the measure of BBB permeability, 
14
C-sucrose and 
radioactive labelled albumin was injected. Subsequently radioactivity was 
measured in plasma and in the brain (Banks et al., 2015). Both these studies 
detect BBB permeability by investigating albumin distribution to the brain. 
Albumin (67 kDa) is ~7nm (Sarin, 2010), therefore, the injection of 75 nm 
green fluorescent liposomes might be too large to move across the BBB even 
by paracellular diffusion in the case of disruption of TJ proteins. 
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Recently, Bien-Ly et al. (2015) investigated the BBB permeability in four 
different mouse models of Alzheimer’s disease and in a mouse model of 
multiple sclerosis. In the model of multiple sclerosis, both increased passage 
of injected antibodies, extravasated IgG, and albumin was observed. This 
was contrasted in the different mouse models of Alzheimer’s disease in 
where no change in permeability was observed compared to control animals 
to any of the injected radioiodinated molecules (3 kDa dextran, 67 kDa 
albumin, and 150 kDa IgG) or different antibodies. However, when the mice 
were treated with LPS 6 hours prior to termination, a significant increase in 
BBB passage of 3 kDa dextran was observed. Furthermore, when post-
mortem brains of Alzheimer’s disease patients were compared with control 
samples, no differences were observed in the amount of plasma proteins 
leakage in micro infarcts. Increased leakage would indicate areas with 
impaired BBB (Bien-Ly et al., 2015). The results of the study by Bien-Ly et 
al. (2015) is thereby questioning the general belief that increased BBB 
permeability is present in both Alzheimer’s disease patients and mouse 
models of Alzheimer’s disease and that this could contribute to disease 
progression and increase delivery of therapeutics. However, it should still be 
noted that multiple studies report increased Evans blue extravasation and 
increased deposition of major plasma proteins like IgG, and fibrinogen in 
brains of other transgenic mouse models of Alzheimer’s disease and in post 
mortem samples from Alzheimer’s disease patients (Dickstein et al., 2006, 
Paul et al., 2007, Ryu and McLarnon, 2009, Biron et al., 2011, Merlini et al., 
2011). These contradicting results underline the great diversity existing 
between different animal models and the actual pathology of the disease seen 
in humans, and certainly open for more investigations.  
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Chapter 6. Conclusion and future 
perspectives 
Study I. Four different experimental setups of the murine BBB were 
successfully established and characterised. The mBCECs express major 
basement membraneproteins in vitro, and the expressions of laminin α5 and 
collagen IV α1 were regulated by the culture conditions. For future studies, 
the contribution of the pericytes and astrocytes to the synthesis of basement 
membrane proteins would give valuable information about the basement 
membrane composition. However, before initiation of such experiments, an 
enriched astrocyte culture with few contaminating microglia cells would be 
needed. This also applies for the pericyte culture, in which microglial cells 
consistently were observed at varying degrees between isolations.  
Study II. The mBCECs had low expression of the FcRn. Future studies 
should include investigations on the beta-2 microglobulin (β2m) expression 
by the mBCECs, since β2m is important for the function of FcRn. Moreover, 
more evaluations are needed on whether the expression of recombinant FcRn 
reflects de facto transport of IgG.    
Study III. “The neurodegenerative insult induced by excitotoxicity led to 
inflammation and accumulation of iron-containing microglia in the SNpr. 
The microglia probably act to scavenge excess iron originating from 
degrading neurons, glia and invading ferritin- and ED1- immunoreactive 
macrophages, but when their capacity is exceeded iron accumulates in the 
neurons as evinced from the larger content of neuronal ferritin. In contrast, 
no change in ferroportin expression was observed, which could be the result 
of counteracting regulation of its expression, i.e., increased post-
transcriptionally expression via its regulation by IRE and a decreased post-
translational expression via interaction with hepcidin at the cellular 
membrane“ (Thomsen et al., 2015b).  
 
Study IV. The neurodegeneration induced by excitotoxicity was 
accompanied by increased BBB permeability as evaluated by the presence of 
endogenous albumin within the brain parenchyma. No apparent permeability 
was observed by injection of 75 nm green fluorescent liposomes 2 hours 
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prior to termination on post-surgery day 28 and 91. In future studies I would 
investigate the tempero-spatial aspect of the BBB permeability, and the size 
dependency by injection of different molecules with a size variation up until 
75 nm. Increased expression of Icam1 and Timp1 was also observed. In vitro 
the increased expression of Icam1 was seen in rBCECs and astrocytes, and 
increased expression of Timp1 was seen in pericytes and astrocytes 
suggesting that these cells are, at least partly, responsible for the increased 
expression of Icam1 and Timp1 seen in vivo. Therefore to evaluate if the 
increased expression of Icam1 and Timp1 distributes to the identical cell 
types in vivo immunolabeling is needed. Furthermore, to quantify the 
expression of basement membrane proteins in vivo, I would support the gene 
expression analyses with Western blot analyses.  
 53 
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Chronic inﬂammation in the substantia nigra (SN) accompanies conditions with progressive neurodegeneration.
This inﬂammatory process contributes to gradual iron deposition thatmay catalyze formation of free-radicalme-
diated damage, hence exacerbating the neurodegeneration. This study examined proteins related to iron-storage
(ferritin) and iron-export (ferroportin) (akametal transporter protein 1,MTP1) in amodel of neurodegeneration.
Ibotenic acid injected stereotactically into the striatum leads to loss of GABAergic neurons projecting to SN pars
reticulata (SNpr), which subsequently leads to excitotoxicity in the SNpr as neurons here become vulnerable to
their additional glutamatergic projections from the subthalamic nucleus. This imbalance between glutamate and
GABA eventually led to progressive shrinkage of the SNpr and neuronal loss. Neuronal cell death was accompa-
nied by chronic inﬂammation as revealed by the presence of cells expressing ED1 and CD11b in the SNpr and the
adjacent white matter mainly denoted by the crus cerebri. The SNpr also exhibited changes in iron metabolism
seen as a marked accumulation of inﬂammatory cells containing ferric iron and ferritin with morphology corre-
sponding to macrophages andmicroglia. Ferritin was detected in neurons of the lesioned SNpr in contrast to the
non-injected side. Compared to non-injected rats, surviving neurons of the SNpr expressed ferroportin at un-
changed level. Analyses of dissected SNpr using RT-qPCR showed a rise in ferritin-H and -L transcripts with in-
creasing age but no change was observed in the lesioned side compared to the non-lesioned side, indicating
that the increased expression of ferritin in the lesioned side occurred at the post-transcriptional level. Hepcidin
transcriptswere higher in the lesioned side in contrast to ferroportinmRNA that remained unaltered. The contin-
uous entry of iron-containing inﬂammatory cells into the degenerating SNpr and their subsequent demise is
probably responsible for iron donation in neurodegeneration. This is accompanied by only a slight increase in
neuronal ferritin and not ferroportin, which suggests that the iron-containing debris of dying inﬂammatory
cells and degenerating neurons gets scavenged by invading macrophages and activated microglia to prevent
an increase in neuronal iron.
© 2015 Elsevier Inc. All rights reserved.
Introduction
Conditions with progressive neurodegeneration in the substantia
nigra (SN) like Parkinson's disease (PD) and pantothenate kinase-
associated neurodegeneration (aka neurodegeneration with brain
iron accumulation (NBIA) formerly Hallervorden–Spatz disease) are ac-
companied by chronic inﬂammation (Hayﬂick et al., 2006; Rouault,
2013; Andersen et al., 2014; Zecca et al., 2004; Levi and Finazzi, 2014),
which contributes to gradual deposition of iron in affected brain areas
(Andersen et al., 2014). The chronic deposition of ironmay catalyze for-
mation of free-radical mediated damage, hence gradually exacerbating
the neurodegenerative stage (Filomeni et al., 2012). A mechanism by
which iron can accumulate in brain areas with neurodegeneration
is through the accumulation of iron-containing inﬂammatory cells
such as macrophages (Rathnasamy et al., 2013). The macrophages
phagocytose damaged neurons and subsequently undergo apoptosis
and deposit their iron in the extracellular space (Neher et al., 2011;
Reif and Simmons, 1990; Wirenfeldt et al., 2007; Tabas et al., 2009;
Rathnasamy et al., 2013). This may interfere with the otherwise healthy
neurons causing reactive oxygen species (ROS)-mediated damages,
ranging from acute interference with the neuronal cellular membrane
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and rapid cell death to chronic changes like post-translational modiﬁca-
tion of neuronal proteins e.g., propagation of alpha-synuclein oligomer
formation and subsequent aggregate formation (Uversky et al., 2001;
Riedlerer, 2004).
We recently reviewed the handling of iron in brain regions with
extensive iron accumulation (Andersen et al., 2014). Iron is probably
released into the extracellular space from dying neurons, apoptotic
macrophages that have migrated into the brain, and glial cells. Iron
may bind to transferrin which then facilitates the uptake of iron in
healthy neurons containing transferrin receptors. This uptake mecha-
nism is expected to cease via down-regulation of the neuronal receptor
in conditions with ample iron (Moos et al., 1998). Neurons also take up
non-transferrin bound iron (NTBI) that is unlikely to be lower in iron ex-
cess (Pelizzoni et al., 2011, 2012). The neuronal uptake of NTBI will in-
duce ferritin expression as a means to scavenge the iron accumulation
(Rouault, 2013). As ferroportin excretes ferrous iron across the cellular
membrane, neurons may regulate their iron content by excretion.
Theoretically the neurons would also increase their expression of
ferroportin in conditions with iron-overloading, as the ferroportin
mRNA has an iron-responsive element (Zhang et al., 2009). Ferroportin
is widely expressed in neurons of the CNS and is often co-expressed
with transferrin receptors in neurons thought to contain large amounts
of iron, e.g., neurons of themedial habenular nucleus and neurons of the
interpeduncular nucleus (Moos and Rosengren Nielsen, 2006; Moos
et al., 1998). Counteracting the signiﬁcance of neuronal ferroportin
in pathological conditions, hepcidin, which is a hormone secreted
from hepatocytes in inﬂammatory conditions and known to post-
translationally down-regulate the expression of ferroportin (Nemeth
et al., 2004), could enter inﬂamed brain regions with a compromised
blood–brain barrier (BBB), and hence impede the function of ferroportin
(Andersen et al., 2014).
The aim of the present study was to investigate the expression of
ferritin and ferroportin in an experimental in vivo model of neurode-
generation with inﬂammation in the brain (Sastry and Arendash,
1995). In this model, ibotenic acid, a glutamate agonist, is injected into
the striatum, which leads to cell death among a great number of
GABAergic neurons projecting to neurons of the substantia nigra pars
reticulata (SNpr). In turn, this will result in an overstimulation of
these SNpr neurons by glutamate projecting from neurons of the nucle-
us subthalamicus. Eventually, this imbalance between glutamate and
GABA leads to the death of the SNpr neurons and chronic inﬂammation
in this site remote in distance from the injection site of ibotenic acid. The
resulting pathology of the SNpr is followed by a signiﬁcant 42% increase
in total iron when measured as milligram iron per milligram protein
after 1 month (Sastry and Arendash, 1995). We hypothesized that the
timedependent increase in cellular iron in the SNprwith chronic neuro-
degeneration and accompanying inﬂammation would lead to changes
in ferroportin and ferritin levels to facilitate neuronal iron export and
storage, respectively.
Materials and methods
Animals
Forty-six male Wistar rats (Charles River Laboratories, Wilmington,
DE) weighing 250–300 g were housed in cages at the Animal
Department of Aalborg University Hospital under constant temperature
and humidity conditions and a 12 hour light/dark cycle with free access
to food and water. The handling of the animals in this study was
approved by the Danish Experimental Animal Inspectorate under the
Ministry of Food and Agriculture.
Surgical procedure
Ibotenic acid was stereotactically injected in quadruplicate into the
striatum, which leads to loss of GABAergic neurons in the striatum
including their ﬁbers projecting to the SNpr (Fig. 1A) (Sastry and
Arendash, 1995). The rats were anesthetized using hypnorm–dormicum
(20mg/100 g) injected subcutaneously and placed in a stereotactic appa-
ratus. The skin was incised along the midline exposing the skull. Ibotenic
acid (Sigma-Aldrich)was injected using a 10 μl Hamilton Syringe in doses
of 5 μg dissolved in 1 μl PBS into the left striatum at two depths in each
drill hole at coordinates 0,35; 3,05; 4,2 and 5,5 mm (anterior; lateral;
ventral) and −1,2; 3,65; 4,5 and 6,2 mm (anterior; lateral; ventral)
relative to bregma using a stereotactic atlas for orientation (Paxinos and
Watson, 1986).
Tissue preparation
At post-surgery (P) day 3 (n=8), day 7 (n=5), day 28 (n=4), and
day 91 (n=8), the ratswere euthanizedwith anoverdose of hypnorm–
dormicum injected subcutaneously and transcardially perfused via the
left ventricle, ﬁrst with saline and then with 4% paraformaldehyde in
0.01 M potassium phosphate-buffered saline (KPBS), pH 7.4. The brains
were dissected and post-ﬁxed in 4% paraformaldehyde overnight at
4 °C. A control group of non-injected rats was also included and exam-
ined corresponding to post-surgery days 3 (n = 3) and 91 (n = 8).
Serial coronal sections (40 μm) through striatum and SN were cut on a
cryostat and collected free-ﬂoating in 0.1 M PBS, pH 7.4 in a sequential
series of six. For RT-qPCR analyses, rats were euthanized with an over-
dose of hypnorm–dormicum injected subcutaneously at post-surgery
interval day 91 (n = 4), and the brains rapidly dissected on ice under
a dissecting microscope to isolate the ventral mesencephalon contain-
ing the SNpr from both the operated and non-operated sides. The
ventral mesencephalon containing the SNpr from age-matched non-
injected rats was similarly isolated bilaterally (n = 6).
Cresyl violet staining
Cresyl violet staining was used to quantify neurodegeneration. The
sections were washed in KPBS three times and then immersed in a
0.5% gelatin solution, mounted on glass slides and dried. Subsequently,
they were stained for 5 min in cresyl violet and rinsed in running
tap water. The sections were then dehydrated in graded alcohols,
dried and sealed in Pertex Mounting Media. To quantify the degenera-
tion of the SNpr, the width was measured using the center of the
interpeduncular nucleus as a reference of orientation. A horizontal line
and a line at an angle of 45° through each SN were measured to divide
the SNpr into a ventro-medial and a dorso-lateral part (Fig. 2A).
Immunohistochemistry
The sections were pre-incubated in blocking buffer consisting of 3%
swine serum diluted in 0.01 M KPBS with 0.3% Triton X-100 (Sigma)
for 30 min at room temperature to block any unspeciﬁc binding. The
sections were then incubated overnight at 4 °C with primary antibodies
diluted in blocking buffer: Mouse anti-rat CD11b (OX42) (Serotec)
diluted 1:100,mouse anti-rat CD68 (ED1) (Abcam)diluted 1:100, rabbit
anti-human ferritin (Dako) diluted 1:200, and rabbit-anti ferroportin
(Abboud and Haile, 2000) diluted 1:1000. The polyclonal antibody
raised against ferritin also reacts with both isotypes of rat ferritin
(Hansen et al., 1999). Next day, the sections were incubated for
30 min at room temperature with biotinylated goat anti-mouse immu-
noglobulin (Dako) or biotinylated swine anti-rabbit immunoglobulin
(Dako) both diluted 1:200 in KPBS. Binding of the antibodies was
visualized using the ABC-system and 3,3′-diaminobenzidine tetrahy-
drochloride (DAB) (Moos et al., 2006).
Iron staining
The Prussian blue-DAB staining method was used to demonstrate
ferric iron (Moos et al., 2006). In brief, sections were treated with 2%
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hydrochloric acid to release ferric ions from binding proteins. These
ions then react with potassium ferrocyanide to produce the insoluble
ferric ferrocyanide compound. To enhance the signal cells were post-
intensiﬁed using DAB.
RT-qPCR
Total RNA was extracted from the dissected SNpr using the GeneJET
RNA Puriﬁcation Kit (Thermo Scientiﬁc) and treated with DNase I
enzyme according to themanufacture's protocol. DNA free RNA samples
were used as a template for cDNA synthesis, whichwas carried out with
the RevertAid Premium First Strand cDNA Synthesis Kit (Thermo
Scientiﬁc). Quantitative RT-PCR was performed with primers speciﬁc
for ferritin L (Ref. sequence: NM_031701.2, forward CTACAGGCTCTTGT
GAGGACTTGAC; reverse AGTAGGAACTGTTAGCGGCAGTTTG), ferritin
H (Ref. sequence: NM_031329.2, forward CTGACTATGCGGAAAGAGTC
GACAG; reverse AGAGGAATCTCCTGGGCTACTTCAG), ferroportin (Ref.
sequence: NM_031591.1, forward ATTCTATAAGGACGATGCGCTGGTG;
reverse GCTGTTCAGTATCACGGTGCATTTG), hepcidin (Ref. sequence:
NM_022712.1, forward TGGATCAAGCCAGATCAGCATTCTC; reverse TTTC
TTCCTCATCTGCAGCCAGTTT), and β-actin (Ref. sequence: NM_031144.
3, forward CCTCTGAACCCTAAGGCCAACCGTGAA; reverse AGTGGTACGA
CCAGAGGCATACAGGG). β-Actin was used as a housekeeping control
gene for normalization purpose. All primerswere synthesized by TAGCo-
penhagen (DK). 1 μL cDNA, and 10 pmol of each primer were used for
every PCR reaction togetherwith theMaxima™ SYBRGreen qPCRMaster
Mix (Thermno Scientiﬁc) in aﬁnal reaction volume of 20 μL. The reactions
were run in Mx3000P instrument (Agilent) and the following program
was used: 1×: 95 °C 10 min; 40×: 95 °C 30 s; 60 °C 30 s; 72 °C 30 s. All
products were veriﬁed by the melting curve, which was made using a
default program. The control reaction (RT-) was performed identically
except for the fact that 1 μL total RNA was used instead of cDNA as a
template. The relative quantities of cDNA in the analyzed samples were
calculated by the method of Pfafﬂ (Pfafﬂ, 2001).
Statistical analysis
Data were analyzed by the GraphPad Prism 5.0 software. Data were
presented as mean ± SEM and the difference among the means was
determined using a onewayANOVAwith Tukey'smultiple comparisons
post hoc test. A probability value of p b 0.05was considered to be statis-
tically signiﬁcant.
Results
Neurodegeneration
Injection of ibotenic acid into the striatum leads to loss of GABAergic
neurons in the striatum, including their ﬁbers projecting to the SNpr
(Fig. 1A) (Sastry and Arendash, 1995). This loss of the striatal neurons
results in a robust shrinkage of the striatum and overlaying cerebral
cortex, which could be observed by the naked eye when brains were
examined on experimental day 91 (Fig. 1B). Furthermore as a conse-
quence of the loss of striatal neurons, the nigral neurons become vulner-
able to glutamatergic projections from the subthalamic nucleus, which
eventually leads to their progressive death and accompanying inﬂam-
mation (Fig. 1A). In the rat, the ED1 immunoreactivity is predominantly
expressed by monocytes that migrate into the brain during inﬂamma-
tion and transforms into phagocytotic macrophages that subsequently
may undergo apoptosis and lease their metal content (Andersen et al.,
2014). Accordingly, ED1 immunoreactive cells are virtually only detect-
able in brain regions with inﬂammation, which is in contrast to CD11b
positive inﬂammatory cells that are seen in both resting and activated
microglia, brain macrophages and monocytes. ED1 positive inﬂamma-
tory cells were observed in both striatum and ﬁbers projecting to the
SNpr during the entire experimental period (Figs. 1C–D) and in the
SNpr already from experimental day 3. The ED1 positive brain macro-
phages seen in the areas containing ﬁbers projecting to the SNpr were
Fig. 1. Injection of ibotenic acid in striatum leads to neurodegeneration in substantia nigra pars reticulata (SNpr). A. SNpr receives dual innervation consisting of inhibitoryGABAergic axons
from striatum (red) and excitatory glutamatergic axons from the subthalamic nucleus (STN) (green). Chemical lesion of striatum causes over-stimulations of SNpr by the projections from
STN which eventually leads to neurodegeneration accompanied by inﬂammation. B. The chemical lesion of striatal neurons with ibotenic acids leads to profound neuronal death, inﬂam-
mation and eventual shrinkage of the brain corresponding to the region containing the striatumand overlaying cerebral cortex, which is observable by the bare eye (asterisk). C. Increased
ED1 immunolabeling in the diencephalon containing the projections from the striatum to the SNpr (square) on experimental day 91. The affected SNpr is also seen (asterisk). D. ED1
immunoreactive cells shown at high-power magniﬁcation from the area marked in C.
110 M.S. Thomsen et al. / Neurobiology of Disease 81 (2015) 108–118
often seen near post-capillary venules in good accordance with that the
cells migrate into the brain via the transvascular route (c.f. Milligan
et al., 1991). The chronic element of the degenerative process in the
SNprwas also reﬂected in that a reduction in the size of this brain region
occurred gradually during the post-surgery period (Fig. 2D). Hence, a
signiﬁcant decrease in the width of the SNpr measuring approximately
1 mm in the non-lesioned side (Paxinos and Watson, 1986) was ob-
served, which reﬂected the maximal reduction in the SNpr (Fig. 2D).
When examining the cresyl violet stained sections, the SNpr of the op-
erated side contained fewer neurons compared to those of non-
operated animals (Figs. 2B–C). The cresyl violet stained sections also
contained multiple inﬂammatory cells identiﬁed by their small nuclei
(Fig. 2B).
Neuroinﬂammation
The progressive neuronal death in the SNpr was accompanied by
the presence of inﬂammatory cells that clearly exceeded the number
present in the non-lesioned side throughout the experimental period
as veriﬁed from the immunoreactivity of ED1 and CD11b immunoreac-
tive cells being present in the lesioned SNpr already from experimental
day 3 (Figs. 3, 4). In the inﬂamed SNpr, the individual ED1 immunoreac-
tive brain macrophages displayed signs of amoeboid cells probably
reﬂecting their nature as monocytes that have migrated into the brain
(Figs. 3F–G). The number of ED1 immunoreactive brain macrophages
in the affected SNpr was slightly increased already from P3, but from
then on the number increased and reached a maximum at the end of
the observation period on post-surgical day 91 (Fig. 3E). Thiswas clearly
opposed in the absence of ED1 immunoreactive brain macrophages on
the non-lesioned SNpr (Fig. 3F). The ED1 immunoreactive brain macro-
phages were also seen in the crus cerebri (Fig. 3G), which suggests that
the macrophages migrated into the SNpr from the subarachnoid space
beside from migrating through post-capillary venules. The crus cerebri
of the non-lesioned side was unaffected (Fig. 3H). Like that seen with
ED1, the number of activated CD11b immunopositive microglia in the
affected SNpr was increased from P3 and remained elevated during
the entire post-surgical period. The presence of inﬂammation in the
crus cerebri was also evident when examining sections stained for
CD11b immunoreactivity (Fig. 4). The individual CD11b immunoreac-
tivemicroglia displayed signs of activation seen as retraction and hyper-
trophy of their peripheral processes, but the CD11b also displayed the
morphology of migrating brain macrophages (Figs. 4F–G).
Fig. 2. Progressive neurodegeneration is observed in substantia nigra pars reticulata (SNpr). A. Standardized measurement of the SNpr. The interpeduncular nucleus marked with an as-
teriskwas used as a reference point for laying a horizontal line perpendicular to a vertical line cutting through the cerebral aqueduct and the interpeduncular nucleus. An angle of 45° from
this horizontal line cutting through the SNprwas used formeasuring thewidth. B,C. The SNpr of the lesioned (B) and non-lesioned (C) sides shown at highmagniﬁcation. The affected SNpr
contains fewer neurons and a robust inﬁltration of inﬂammatory cells. D.When comparing the diameters (dm) of the SNpr between the lesioned and non-lesioned sides, it is evident that
the diameter of the SNpr chronically shrinks. This is shown by the progressive decrease in the percentile difference between the diameters of the SNpr on the two sides. Data is represented
as mean ± SEM. **p b 0.001; ***p b 0.0001.
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Iron metabolism
The distribution of iron, ferritin and ferroportin in the normal rat
brain has been described in several publications (Benkovic and
Connor, 1993; Burdo et al., 2001; Hill and Switzer, 1984; Moos and
Rosengren Nielsen, 2006; Wu et al., 2004). In brief, histological iron
and ferritin are detectable in the normal brain in glial cells like oligoden-
drocytes and resting microglia but not in neurons and astrocytes until
aging (Benkovic and Connor, 1993). The increase in total iron that oc-
curs in the inﬂamed SNpr following injection of ibotenic acid (Sastry
and Arendash, 1995) is therefore not followed by a general increase in
histological detectable iron in all cells in this region. Ferroportin was
seen in neurons and oligodendrocytes but not regularly in other glial
cells. The distribution of histological iron and ferritin differed between
the lesioned and non-lesioned sides in that cells with morphological
similarity with brain macrophages and activated microglia could be
Fig. 3. Inﬁltration of ED1 immunoreactive cells in substantia nigra pars reticulata (SNpr) of the lesioned side. Representative pictures of sections from the substantia nigra pars reticulata
(SNpr) showing ED1 immunoreactivity. Illustrations are taken on post-surgery days 3 (A,B), and 91 (C–H). Already from day 3, ED1 immunoreactivity is observed in the lesioned side
(A, arrows), whereas the non-lesioned side is devoid of ED1 immunoreactivity (B), crus cerebri is marked with an asterisk. C,D. On experimental day 91, strong ED1 immunoreactivity
is conﬁned to the lesioned SNpr and the adjacent white matter of the crus cerebri (C, asterisk). This is clearly opposed in the absence of ED1 immunoreactivity on the non-lesioned
side (D). The SNpr and crus cerebri of the lesioned (E,G) and non-lesioned (F,H) sides shown at highmagniﬁcation. The non-lesioned side does not contain ED1 immunoreactivity in either
SNpr (F) nor in crus cerebri (H). The ED1 immunoreactive inﬂammatory cells in the lesioned side are round or amoeboid in shape corresponding to their origin as brainmacrophages that
have migrated into the brain.
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seen in the inﬂamed SNpr (Figs. 5A,D). At the cellular level, the SNpr of
the lesioned side dramatically differed in that ironwas seen in cells with
morphology corresponding to microglia and amoeboid macrophages
and not in oligodendrocytes. These iron-positive microglia and
macrophages were mostly observed in the SNpr and not in the crus
cerebri (Fig. 5A). Iron was not detected in surviving neurons of
the SNpr on the lesioned side. Ferritin immunolabeling was present
among inﬂammatory cells withmorphology corresponding to amoeboid
macrophages and microglia in both SNpr and the crus cerebri on the
lesioned side (Figs. 5C–D). In contrast to that of iron, ferritin was also
detected in cells with morphology corresponding to neurons on the
lesioned side, especially on day 91 (Figs. 5F–G). In comparison with
neurons, macrophages and microglia were however individually much
more immunoreactive.
Ferroportin was seen in neurons of the mesencephalon in both the
normal and the operated brain in regions like the oculomotor nucleus,
Fig. 4. Activated microglia cells can be observed in substantia nigra pars reticulata (SNpr) of the lesioned side. Representative pictures of sections from the SNpr showing CD11b immu-
noreactivity. Illustrations are taken on post-surgery days 3 (A,B), and 91 (C–H). Already from day 3, CD11b immunoreactivity is higher in the lesioned side (A, arrows) compared to the
non-lesioned side that contains CD11b immunoreactive resting microglia (B). C–D. On experimental day 91, CD11b immunoreactivity is conﬁned to the lesioned SNpr and the adjacent
white matter of the crus cerebri (C, asterisk), the non-lesioned side contains resting microglia cells (D). The CD11b immunoreactivity in SNpr of the lesioned (E) and non-lesioned
(F) sides shown at high magniﬁcation revealing activated round microglia cells in the lesioned side as indicated by the arrow. G. Crus cerebri of the lesioned side contains CD11b
immunoreactivity. These cells are beside from being locally recruited and activated CD11b immunoreactive microglia cells, also CD11b immunoreactive inﬂammatory cells that are
round or amoeboid in shape (arrows and inset) corresponding to their origin as brain macrophages that have migrated into the brain. H. The crus cerebri in the non-lesioned side is
completely devoid of CD11b immunoreactivity.
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red nucleus, and interpeduncular nucleus (Fig. 6A). In the SNpr and SNpc,
the neuronswereweakly labeled in the normal brain. In the lesioned side,
ferroportin was not detected in cells with morphology corresponding to
amoeboid macrophages or activated microglia. It was the clear impres-
sion that the number of neurons of the SNpr labeled with ferroportin
was unaltered compared to the non-lesioned side (Figs. 6B–C), suggesting
that the neurons did not upregulate their ferroportin expression or in-
creased their content of ferroportin protein in response to the increase
in iron.
RT-qPCR analyses of the dissected SNpr showed that transcripts
of ferritin H and ferritin L were equally abundant in the rat brain
on post-surgery days 0 and 91 when comparing the injected and
non-injected sides. On day 91, both ferritin H and L were signiﬁcantly
higher expressed than on day 0. The expression of ferroportin
was lower in the lesioned side on day 91 although this difference was
non-signiﬁcant when compared to the non-lesioned side. Hepcidin
was signiﬁcantly higher expressed on the lesioned side on day 91
(Fig. 7).
Fig. 5. Accumulation of ferric iron and ferritin in the lesioned substantia nigra pars reticulata (SNpr) and thewhitematter of the crus cerebri. Representative pictures of sections from SNpr
showinghistological detectable ferric iron (A,B) and ferritin immunoreactivity (C–G) on post-surgery day 91. In the lesioned side (A) ferric iron is present in the oligodendrocytes and cells
with microglia cell morphology as highlighted in the inset, in the non-lesioned side (B) iron is conﬁned to the oligodendrocytes and their ramiﬁcations. C. The altered iron-distribution is
reﬂected in the ferritin immunolabeling in that the labeling is reduced in the SNpr but present in thewhite matter of the crus cerebri (asterisk) of the lesioned side (left) compared to the
non-lesioned side (right). D,E. The SNpr and crus cerebri (asterisk) shown at higher magniﬁcation reveal the presence of round or amoeboid cells (arrows) in the crus cerebri of the
lesioned side (D) corresponding to ferritin immunoreactive brain inﬂammatory cells that have migrated into the brain. There is barely any ferritin immunoreactivity in crus cerebri of
the non-lesioned side (E). F,G. SNpr of the lesioned side shown at high magniﬁcation, revealing ferritin immunoreactivity in both neurons (arrows) and microglia cells (arrowheads).
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Discussion
Experimental induced chronic neurodegeneration and inﬂammation
The excitotoxicity of the glutamatergic projections from the subtha-
lamic nucleus denotes a powerful mechanism for neuronal cell death in
the SNpr that can be prevented by supplying the GABA receptor agonist
muscimol (Danbolt, 2001; Saji and Reis, 1987). Other contributing
factors for neurodegeneration in the SNprwere the adjoining inﬂamma-
tory process and iron-deposition. The affected SNpr and neighboring
white matter revealed a chronic inﬂammatory process containing mac-
rophages expressing ED1 and CD11b immunoreactive microglia during
the entire observation period, including a dramatic inﬂammation even
91days after injection of ibotenic acid, which signiﬁes this experimental
model for studies of chronic neurodegenerationwith inﬂammation. The
appearance of ED1positivemacrophages in adjacentwhitematter over-
lying the SNpr suggests that the macrophages entered the SNpr by
chemoattraction subsequent to their migration into the subarachnoid
space. The SNpr also revealed a change in iron metabolism seen as a
prominent content of inﬂammatory cells withmorphology correspond-
ing to macrophages and microglia cells containing ferric iron and ferri-
tin. Iron-containing cells with morphology corresponding to microglia
were only seen in the SNpr and not in the adjacent crus cerebri. There
was a light tendency towards higher ferritin, but not of ferroportin, in
neurons of the affected SNpr, which suggests that the resulting iron ac-
cumulation led to affection of scavenging inﬂammatory cells more than
neurons. This notion gains support from the observation that macro-
phages and microglia were much more immunoreactive than neurons.
Macrophages can be characterized with respect to their detrimental
(M1) or beneﬁcial (M2) activity towards the diseased tissue (Kroner
et al., 2014; c.f. Stoger et al., 2010). While true phenotypic markers of
these two types are difﬁcult to identify, the classiﬁcation is relevant
with respect to the macrophages' capability to synthesize nitric oxide
(NO) as M1 and not M2. Inducible nitric oxide synthetase (iNOS) is an
enzyme responsible for NO release in many pathological conditions of
the brainwith invasion of ED1 immunoreactivemacrophages appearing
in high density (Hernandez-Romero et al., 2012; Li et al., 2012; Pintado
et al., 2011). NO interacts with the binding of iron to ferritin, as NO can
Fig. 6. Unchanged ferroportin expression in substantia nigra pars reticulata (SNpr) of the lesion side. A. Representative picture of section from the mesencephalon showing ferroportin
immunoreactivity on post-surgeryday 91with the lesioned side shown to the left. The protein is present inneuronswidespread in themesencephalon like those of the oculomotor nucleus
(A, inset) and interpeduncular nucleus (asterisk). Ferroportin immunoreactivity is also vaguely seen in neurons in the substantia nigra pars compacta (SNpc) and pars reticulata (SNpr).
B–C, When shown at high magniﬁcation, it is apparent that ferroportin immunolabeling is seen lightly in neurons of the SNpr on both the lesioned (B) and non-lesioned (C) sides.
Ferroportin is not seen in the white matter of the crus cerebri (asterisk). D,E. SNpr shown at high magniﬁcation, there is no apparent difference in the ferroportin immunoreactivity
when comparing the lesioned (D) and non-lesioned sides (E).
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release iron from ferritin causing iron to appear on reactive loosely
bound forms (Reif and Simmons, 1990). Given the ample presence of
iron and ferritin in the SNpr, the presence of iNOS positive M1 macro-
phages will make a strong contribution to amplifying the toxicity of
iron. The inhibitor of iNOS aminoguanidine was shown to attenuate
the neurotoxic effects of ferric iron injected directly into the ventricular
system (Bostanci and Bagirici, 2008). Further studies analyzing the
signiﬁcance of NO released from macrophages in conditions with iron
deposition in the brain are highlywarranted, as inhibitingmacrophages
expressing iNOS could be beneﬁcial to downscaling the effects of the
continuous recruitment of M1 macrophages and their detrimental
effects on the metabolism of iron (Li et al., 2012).
Iron management in neurodegeneration
In the human brain, neurons accumulate iron in areas affected by
neurodegeneration (Dexter et al., 2011; Soﬁc et al., 1988). This accumu-
lation may preferentially occur in intracellular aggregates and granules
(Good et al., 1992a,b), which hardly occurs in the rodent brain during
neurodegeneration. However, rodent neuronswere also shown to accu-
mulate iron to an extent that led to signiﬁcant improvement when
treated with an iron-chelator (Dexter et al., 2011). This would suggest
that iron would accumulate intraneuronally and trigger expression of
either ferritin for storage or ferroportin to increase the efﬂux. We ob-
served a slight upregulation of ferritin in neurons on the lesioned side,
whereas we were unable to detect iron in neurons. The latter observa-
tion was counteracted in the study of Sastry and Arendash (1995),
whodid ﬁnd few neuronswith histologically detectable iron in their ob-
servation period until fourweeks after surgery. The detection sensitivity
of the Prussian blue-DAB staining is clearly lower when compared to
that of ferritin immunolabeling (Moos et al., 2006). Any differences in
iron detection could rely on that iron present in neurons could be on
the limit of detection; but the presence of ferritin in neurons of the
affected side as seen in the present study suggests that they have
increased their iron content. The neurons may also incorporate iron by
molecules non-detectable by the Prussian blue-DAB staining that
mainly detects iron when present on its non-heme, ferric form (Moos
et al., 2006).
Apart from causing possible damage to neurons due to intracellular
accumulation and subsequent propagation of oxidative stress, iron is
damaging in the vicinity of neurons when appearing on its ferrous
form (Rouault, 2013; Andersen et al., 2014; Ward et al., 2014). Ferrous
iron is thought to undergo rapid oxidation to ferric iron in biological
systems, unless capacities are underscoring due to overproduction of
ferrous iron as may occur in acute hemorrhage with lysis of red cells
and degradation of heme from hemoglobin. The chronic inﬂammation
did not ﬁnd evidence for hemorrhage in spite of severe inﬂammation,
but heme-containing proteins are likely to be released from demising
macrophages and make their contribution to stress the capacity of
anti-oxidants to prevent formation of free radicals. Ferrous iron is
toxic in high concentrations due to an increased redox cycling
(Jomova et al., 2010; Nunez et al., 2012), which will increase iron-
catalyzed free radical formation that can induce neuronal damage by
lipid peroxidation of cellular and organelle membranes, axonal dystro-
phy, and eventually necrosis and apoptotic cell death (Nunez et al.,
2012; Rouault, 2013; Ward et al., 2014).
As iron accumulates in the brain bound to ferritin as a result of nor-
mal aging, ferritin detected in the SNpr of the lesioned side is not a result
of the striatal lesion, but because the rats increased in age. The absence
of differences in expression of ferritin H and L between the lesioned and
non-lesioned sides does not preclude a higher level of ferritin as the ac-
cumulation of iron post-translationally increases synthesis of ferritin.
Fig. 7. Expression of ferritin L, ferritinH, ferroportin and hepcidin in substantia nigra pars reticulata (SNpr). RT-qPCR-analyses for ferritin L, ferritinH, ferroportin and hepcidin in substantia
nigra pars reticulata on days 0 (non-operated) and 91 after injection. Left represents the lesioned side of the brain and right the non-lesioned side. There are signiﬁcantly more ferritin
transcripts in SNpr after 91 days, which may reﬂect that iron and ferritin post-transcriptionally increase in the brain with increasing age (Focht et al., 1997). There is no difference in
the ferritin expression between the lesioned and non-lesioned sides on day 91. Ferroportin is lower in the operated side and overall lower on post-surgery day 91. There is signiﬁcantly
more hepcidin expressed in the lesioned side compared to the non-lesioned side on post-surgery day 91. The data are shown as fold change over actin and the data is represented as
mean ± SEM. *p b 0.05; **p b 0.001.
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Ferritin transcripts were higher on day 91 compared to day 0, which is
in good accordance with that ferritin expression increases in the brain
with increasing age (Benkovic and Connor, 1993).
In addition to the participation of ferroportin in intestinal absorption
and circulatory iron-homeostasis via expression in duodenal enterocytes,
hepatocytes andmacrophages, ferroportin is also expressed in neurons of
the CNSwith signiﬁcant regional variations (Burdo et al., 2001;Moos and
Rosengren Nielsen, 2006; Wu et al., 2004). Ferroportin is the only de-
scribed protein known to mediate cellular efﬂux of iron, which would
makemismatch in the functionality of ferroportin in the CNS a possibility
for iron to get trapped inside neurons leading to their lack of capability to
excrete iron. In turn this incapability to export iron from cells would lead
to accumulation of iron inside CNS and pose neurons to an increased
risk for ROS-mediated damage. However, despite that ferroportin was
detectable in neurons of the SNpr, their immunoreactivity was however
not higher than in the control side. This observation was conﬁrmed in
the RT-qPCR analysis wherein differences between the two sides were
non-signiﬁcant, although there was a tendency towards ferroportin
being lower in the lesioned side, which can be explained by the loss of
neurons in the SNpr.
Experimental neurodegeneration has never been correlated directly
to changes in neuronal ferroportin expression, but injections of hepcidin
into the lateral ventricle of rats lead to a decrease in neuronal
ferroportin conﬁrming the notion of a degradation of ferroportin in
the presence of hepcidin (Wang et al., 2012). Hepcidin is synthesized
mainly in the liver and to a lesser extent in monocytes ((Nguyen et al.,
2006; Peyssonnaux et al., 2006; Theurl et al., 2008). Conversely,
hepcidin is not synthesized in the brain unless in pathological condi-
tions with inﬂammation (Urrutia et al., 2013; Simpson et al., 2015).
Provided pathological condition within the CNS induces signaling in
the circulation, it is predictable that such activity would subsequently
induce hepcidin in plasma with the likelihood of passing into the
brain if the integrity of the blood–brain barrier is compromised. Condi-
tions with chronic pathology of the CNS leading to migration of iron-
containing macrophages and their subsequent demise as discussed in
previous paragraphs would make it likely that the neurons could suffer
from the accumulation of iron released from dying macrophages
combined with incapability to release iron via ferroportin due to the
presence of hepcidin inside the inﬂamed CNS. Therefore the unaltered
expression of ferroportin observed in the present examination in this
model of chronic neurodegeneration could reﬂect a balance between a
raise in ferroportin post-transcriptionally regulated by the readily iron
access and a post-translational decrease due to hepcidin. Interestingly,
iron deﬁcient animals exhibit unaltered levels of ferroportin expression
(Burdo et al., 2001;Wu et al., 2004), and no changes in the expression of
ferroportin were found in mutated IRP2 mice in spite of regional
increases in brain iron (Wu et al., 2004). These studies may indicate
that robust changes in iron in the CNS would be needed to affect
the ferroportin expression. Moreover, the data of the latter studies
combined with the present also indicate that the regulation of neuronal
iron levels is controlled via changes in ferritin gene translation in condi-
tions with iron accumulation.
Conclusions
The neurodegenerative insult induced by excitotoxicity led to
inﬂammation and accumulation of iron-containing microglia in the
SNpr. The microglia probably act to scavenge excess iron originating
from degrading neurons, glia and invading ferritin- and ED1-
immunoreactive macrophages, but when their capacity is exceeded
iron accumulates in the neurons as evinced from the larger content of
neuronal ferritin. In contrast, no change in ferroportin expression was
observed, which could be the result of counteracting regulation of
its expression, i.e., increased post-transcriptionally expression via its
regulation by IRE and a decreased post-translational expression via
interaction with hepcidin at the cellular membrane.
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